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Abstract
This study investigates the metabolic consequences of a biomarker for mitochondrial myopathies,
using the mouse as a model organism. The studied biomarker is fibroblast growth factor 21 (FGF21),
which is secreted in high amounts from the diseased muscle tissue. It is an endocrine hormone that
regulates lipid metabolism, and in healthy individuals it is mainly secreted from the liver. I utilized
skeletal muscle samples from mice that were either wild type or had a mitochondrial myopathy,
both with or without a whole-body knockout of FGF21. I analysed a data set from a targeted
metabolomic experiment conducted on the skeletal muscle samples. The experiment was performed
by our collaborator Vidya Velagapudi. Additionally I measured protein and mRNA expression of
selected enzymes from the muscle samples.
This study shows, that the cytokine FGF21 contributes to the disease progression of mitochondrial
myopathy. The aspects of pathophysiology it regulates were all found to center on the metabolic
pathway of one carbon (1C) metabolism. Serine de novo synthesis shuttles glucose carbons into
1C metabolism. The transsulfuration pathway produces glutathione using carbon units from the
1C pathway. The results of this study show, that FGF21 mediates the upregulation of alternative
carbon donors in one carbon metabolism, especially serine biosynthesis, and the elevated utilisation
of carbon units in the transsulfuration pathway. Not all of the metabolic changes characteristic of
mitochondrial myopathy were affected by FGF21, e.g. the upregulation of acyl carnitines seen in
mitochondrial myopathy was not affected by the knock-out of FGF21.
Keywords: mitochondrial disease, myopathy, FGF21, biomarker, adPEO, Twinkle, metabolic
pathway, one carbon metabolism, targeted metabolomics, MetaboAnalyst
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1 Introduction
Mitochondria are cellular organelles most often remembered as ”the powerhouse of the cell”. True
to the stereotype, they do dutifully generate most of the ATP any eukaryote needs. A cancer
biologist may often think of mitochondria as the organelles which regulate apoptosis, in the hopes
of reinstating in cancer cells the ability to commit suicide. Nonetheless, upon making a closer
acquaintance with mitochondria one learns that these hard-working old endosymbionts of ours are
involved in a substantial amount of diverse cellular processes beyond oxidative phosphorylation or
the storage and release of calcium ions (Nunnari & Suomalainen 2012). In integrating complex
metabolic and signalling pathways, mitochondria are a profoundly essential and influential part of
the cell (Nunnari & Suomalainen 2012, Zong et al. 2016).
The diversity of mitochondrial functions is mirrored in the diversity and symptomatic variability
of mitochondrial diseases (Gorman et al. 2016). A substantial amount of intermediary metabolism
takes place in mitochondria, and these metabolic pathways have been found to both be affected in
mitochondrial diseases and to contribute to pathogenesis. Studying mitochondrial diseases leads
not only towards better treatment options, but also sheds light on the complex biology of both
mitochondria and the whole cell they inhabit and control.
The fibroblast growth factor 21 (FGF21) has been established as a biomarker for mtDNA main-
tenance and mitochondrial translation disorders, where it is found upregulated in the serum of
patients (Lehtonen et al. 2016, Suomalainen et al. 2011a). FGF21 is termed a ”fasting hormone”,
since it is known to be induced by fasting and it acts to mobilise fatty acids from white adipose
tissue (Inagaki et al. 2007). Although usually originating from the liver (Nishimura et al. 2000), in
these pathologies FGF21 is secreted by the diseased skeletal muscle.
The upregulation of FGF21 was first connected to inherited disease, when it was found to be induced
in mitochondrial myopathy in the Deletor mouse (Tyynismaa et al. 2010). The Deletor is a mito-
chondrial disease model (Tyynismaa et al. 2005), which manifests with a late-onset mitochondrial
myopathy (MM) primarily observed in the skeletal muscle quadriceps femoris (QF). Indeed, FGF21
was secreted directly from the affected muscle fibers. Another feature of the Deletor phenotype are
widespread metabolic changes in its skeletal and heart muscle tissues (Nikkanen et al. 2016). It is
of interest to discern the pathological role of FGF21 in the diseases that present with it, and this
can be studied by inactivating FGF21 from Deletor mouse, by genetically knocking out the gene.
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2 Aims
General aim:
Characterising the metabolic consequences of FGF21 in the mitochondrial myopathy of the mouse.
Specific aims:
1) Exploring methods of analysis and the means to interpret the results, and assessing their suit-
ability for this study.
2) Establishing whether FGF21 act to progress the symptoms of the disease, or to protect the
affected organism from them.
3) Describing the metabolic alterations caused by FGF21.
2
3 Review of literature
3.1 Mitochondrial diseases
Mitochondrial diseases are genetic diseases that harbour mutations in genes whose protein products
localise in mitochondria. The disease course leads to an impairment of cellular energy metabolism,
typically causing symptoms in organs that heavily utilise oxidative phosphorylation. Often the
disease-causing mutation is found directly in one of the proteins associated with the mitochondrial
respiratory complexes I-V, or in proteins involved in mtDNA maintenance or mitochondrial protein
synthesis. Taken all together, these diseases are the most common form of inherited metabolic
disease (Thorburn 2004) and their total prevalence is estimated to be 1 in 5000 (Ylikallio & Suo-
malainen 2012). No curative treatment for them exists (Suomalainen 2011b). A comprehensive
overview on the topic can be found in the recent review by Gorman et al. (2016).
3.1.1 Complexity in the disease manifestation
Mitochondrial diseases are characterised by complexity in both disease manifestation and mecha-
nism. The defectively mutated gene can reside in either nuclear DNA (nDNA) or mitochondrial
DNA (mtDNA). Any inheritance pattern is possible, any organ system can be affected, and symp-
toms are heterogenous – even between patients with similar syndromes. If the mutation is in
mtDNA, also the level of heteroplasmy affects the severity of disease manifestation. Heteroplasmy
refers to the existence of both defective and intact mtDNA content in the cell.
Defects in the same gene can lead to diseases with very different symptoms. E.g. infantile onset
spinocerebellar ataxia (IOSCA) and a form of autosomal dominant progressive external ophthalmo-
plegia (adPEO) both harbour a mutation in the mitochondrial helicase TWINKLE, but the former
is a neurogenerative disorder and the latter a myopathy (muscle disease) (Koskinen et al. 1994,
Suomalainen et al. 1992). The reason for such non-overlapping tissue manifestations in the case of
Twinkle diseases is not known.
Mitochondria are an important site of metabolism within the cell (Nunnari & Suomalainen 2012).
Their metabolic pathways are connected to the cytosol, e.g. through the folate cycle, which runs
partly within the mitochondrial matrix and partly outside of the organelle (Ducker & Rabinowitz
2017). Because mitochondria house ample and interconnected metabolic and signalling pathways,
these should be studied in the context of mitochondrial disease. Different cells in different tissues
inevitably have different metabolomes. Should metabolite levels play a role in disease mechanism,
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will their study lead to insights about the elusive tissue specificity of symptoms.
3.1.2 Progressive external ophthalmoplegia
Progressive external ophthalmoplegia (PEO) is an adult onset mitochondrial myopathy, and its
most visible symptom is the weakening of the extraocular muscles, which results in drooping eyelids.
These symptoms may occur alone, or the patients may develop ataxia, parkinsonism, premature
menopause or depression - depending on the causative gene in question. PEO can be caused by a
range of different mutations in different proteins, and it is characterised by multiple deletions in
the mitochondrial genome in affected tissues. (Copeland 2008, Ylikallio & Suomalainen 2012)
One of the defective proteins in PEO is the TWINKLE helicase, which was first characterised and
reported in Spelbrink et al. (2001), when it was found in conjunction with the disease. Since the
helicase is encoded by nDNA and the impaired allele is dominant, PEO with a TWINKLE defect is
autosomal dominant PEO (adPEO). The defect in TWINKLE leads to repeated mtDNA replisome
stalling and dsDNA breaks (Goffart et al. 2009). The dsDNA repair mechanism then causes a
deletion of DNA at every repaired breakpoint (Srivastava & Moraes 2005), so adPEO is a mtDNA
maintenance disorder. The mtDNA deletions accumulate over the lifetime of the patient, eventually
crossing a phenotypic threshold when symptoms appear.
3.1.3 The Deletor mouse
The Deletor mouse is a model organism for a late onset progressive mitochondrial myopathy, orig-
inally designed in Tyynismaa et al. (2005). It was generated by inserting a TWINKLE patient
mutation (Spelbrink et al. 2001) into a homologous position in the mouse genome. As a mitochon-
drial disease model the Deletor is remarkable and useful because it is based on a patient mutation
and because the phenotype is that of a late onset disease, which does not have many model organ-
isms (Tyynismaa & Suomalainen 2009).
The model was reported to replicate a range of relevant histological, genetic, and biochemical
features of PEO patients (Tyynismaa et al. 2005). These include COX-/SDH+ skeletal muscle
fibres, multiple-sized deletion accumulation at specific sites in the mitochondrial genome in muscle
and brain tissues, and a similar age of onset of the disease when related to the expected lifespan.
The age of onset is 12 months for the Deletor, based on the appearance of histological signs in
skeletal muscle. The mice have a normal lifespan and gross motor performance despite of the
disease.
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3.1.4 The amino acid starvation response
The gene expression of Deletor skeletal muscle was studied in Tyynismaa et al. (2010), and a strong
induction of genes under control of amino acid response elements (AARE) was found, among these
the fibroblast growth factor 21 (FGF21) and the enzyme methylenetetrahydrofolate dehydrogenase
2 (MTHFD2), which acts in the folate cycle. The expression of both these proteins increased with
the progression of the disease, implying their possible involvement in the disease mechanism.
Members of the activating transcription factor (ATF) family bind AARE sites at promoter regions
of genes important for cellular stress reactions, notably upon amino acid limitation. ATF4 is
deemed the master regulator of the following signalling cascade (Kilberg et al. 2005). FGF21 is
mainly regulated by ATF4, through the promoter sequences AARE1–3 (Maruyama et al. 2016).
Because of the involvement of AARE:s found in the Deletor, the myopathy was originally described
as a state of ”pseudostarvation”. However, current knowledge suggests that anabolic biosynthesis
pathways are chronically induced.
3.2 The fibroblast growth factor 21
Fibroblast growth factor 21 (FGF21) belongs within the FGF superfamily into a subgroup which
has endocrine action, together with FGF19 and FGF23. These FGFs share the feature that they
have poor binding affinity to heparin, which makes transport through the circulatory system and
their function as endocrine hormones possible. FGF21 signals via FGF receptors by simultaneously
binding the co-receptor βKlotho (Kharitonenkov & DiMarchi 2017).
FGF21 was discovered in 2000 (Nishimura et al. 2000) and brought to wider attention in 2005 in
a screening panel because of its ability to regulate glycemic control (Kharitonenkov et al. 2005).
It stimulates lipolysis and increases insulin sensitivity, thereby promoting resistance to obesity
(Kharitonenkov et al. 2005) and causing weight loss (Kharitonenkov et al. 2006). There has been a
lot of enthusiastic research centered on the aim of using the protein to treat diabetes and obesity
(Sonoda et al. 2017).
The main source of FGF21 in healthy individuals is the liver in both mice and humans (Nishimura
et al. 2000). FGF21 crosses the blood-brain-barrier and recent results indicate, that both the liver
and the brain regulate the release of the hormone from the liver (Potthoff 2016). However, in
mitochondrial myopathies FGF21 is secreted from skeletal muscle into circulation in such a robust
manner, that is has been established as a biomarker for these diseases (Suomalainen et al. 2011a).
This is an important finding concerning the diagnosis of mitochondrial diseases, where a muscle
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biopsy is standard procedure for diagnosis of muscle manifesting diseaes. Circulating FGF21 can
be detected from a simple blood sample.
FGF21 has been found to mediate the adaptive fasting response through PPARα, promoting torpor
and inducing lipolysis of white adipose tissue and ketogenesis in the liver in mice (Inagaki et al.
2007). As a hormone, FGF21 is still a fairly new object of study and its actions are not well
understood. Even downright paradoxical observations are published, e.g. mild hypoglycaemia in
both FGF21 KO and transgenic FGF21 mice, as pointed out in Kharitonenkov & DiMarchi (2017).
The intricacies of FGF21 signaling are nonetheless being looked into, and regulatory actions of the
hormone obtain new explanations through a more detailed picture of its physiology. One interesting
aspect of it became apparent when it was found upregulated in mitochondrial myopathy: through
the actions of FGF21, the influence of mitochondrial signalling extends from within the confinements
of a single cell to distant tissues in the whole organism.
3.3 Metabolomics
Metabolomics is a younger ’omics field and like the others, e.g. transcriptomics, it has been made
possible by technological advances that permit experiments of larger scale and higher performance.
Instead of tens or hundreds of individual biochemical assays, one single metabolomic experiment
can be performed to obtain a snapshot of the metabolic state in a given biological sample. The
necessary technological advances were made in the synthesis of isotope labelled compounds and in
instrumentation for analytical chemistry, and in the development of computational tools with which
to analyse the measurement output. (Johnson et al. 2016)
The measurements are usually performed using either mass spectrometry (MS) or nuclear magnetic
resonance (NMR) instruments, often coupled to gas chromatography (GC) or liquid chromatography
(LC) for additional separation of the different chemical species. GC is suitable for easily volatile
metabolites. After the physical experiment, preprocessing of the raw data, and thereafter statistical
and bioinformatic analysis is needed to achieve meaningful results. (Liu & Locasale 2017)
3.3.1 Targeted and untargeted approaches
The field is commonly divided into two, based on the approach and the phrasing of research ques-
tions. One large category is untargeted metabolomics, and the other is targeted metabolomics. An
untargeted metabolomics experiment is done without a priori knowledge about which metabolites
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will appear in the measurement. The aim is to identify as many metabolites in the sample as
possible, analogous to shotgun proteomics, and the results are usually qualitative in nature. Iden-
tification of new metabolic compounds is possible in untargeted experiments, though analysis of
mass spectra with complex analyte mixtures can be challenging. (Ebbels & Iorio 2011a)
In targeted metabolomics, the experiment has been optimised for measurement of a specific set of
compounds. Because of this optimisation, detection of each individual metabolite is robust and
the results are usually quantitative. The approach requires prior knowledge about the presence of
the targeted metabolites in the sample. It can be used for validation of results from untargeted
experiments, or else when robust readings for specific metabolites are sought after. Sometimes an
experiment is termed ”semi-untargeted”, implying that the set of measured compounds has been
selected with little bias from biological knowledge. (Liu & Locasale 2017)
3.3.2 Metabolomic experiments yield large sets of data
An untargeted metabolomic experiment produces a large amount of high-dimensional spectral data.
The most time-comsuming part of the untargeted experimental workflow is the preprocessing of this
instrumental data, incorporating operations such as retention time alignment, spectral binning, and
peak picking and annotation (Gowda et al. 2014). The result of preprocessing is a list of identified
metabolites and simply being able to identify them takes all the effort, as is apparent e.g. in the
master’s thesis by Kalogeropoulou (2011). After this, qualitative analysis ensues.
In targeted metabolomics the compound identification and quantitation is a routine and previously
optimised step of the worflow. Nonetheless, also here the most time-consuming affair is data
analysis. This time the data at hand is numerical, so statistical analysis and quantitative approaches
to bioinformatics become applicable and necessary. Simple ”eyeballing” of the data is only a start
to what can be done in terms of analysis (Chadeau-Hyam et al. 2013). The analysis then very
quickly yields an abundance of lists, plots, and tables as results, and navigating the possibilites for
use of analytical tools and therefore keeping track of the obtained results is of importance in both
targeted and untargeted metabolomics.
3.3.3 Working around multiple testing
When performing statistical tests on large sets of data, the type I statistical error of false positives
becomes commonplace. When e.g. comparing the Deletor to WT in this study using a statistical
test, we have approximately one hundred metabolites to analyse and should therefore expect to
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find five false positives on the significance level of α = 5%. Performing many statistical tests in this
fashion is termed multiple testing (Chadeau-Hyam et al. 2013, Mary-Huard & Robin 2011).
There are many adjustments for multiple testing, aiming to correct p-values so that the type I error
rate decreases. The perhaps best known one is the Bonferroni adjustment, which is widely used
but quite strict and conservative (Armitage et al. 2015). Another approach is to calculate false
discovery rates (FDR) in order to estimate the rate of type I error and stay aware of the possibility
of false positives. New methods of FDR estimation are constantly being developed.
Controlling for type I errors in metabolomics is difficult, because the approach to data analysis
is largely explorative. There is no simple and clear predefined hypothesis to be tested, which
could be used to plan for all of the steps of statistical analysis in advance so that the error rate
could be minimised. Rather, the analysis seeks to find interesting features and generate hypotheses
based on these. In this case, adjusting p-values is meaningless because of the complexity of the
analysis (Bender & Lange 2001). Instead, new biological replicates, measurements, and studies,
or complementary independent experiments are needed to validate any findings of a metabolomics
study. Suitable experiments are e.g. measuring mRNA or protein expression levels of those enzymes,
whose substrates have attracted attention in the metabolomic data.
3.4 Tools for metabolomic analysis
A bioinformatician should always have time to just ”play with the data” (personal communication,
Chengyu Liu). No single bioinformatic protocol exists, not even a very thorough one, that could be
used to extract all possible information out of a set of biological data. However, there are specific
tools which have been found generally useful. By testing these tools, the bioinformatician gets
an impression of the data and preliminary results, which guide the selection of further tools and
approaches for a meaningful analysis. Knowledge is needed on which tools, why, and how to use,
and how to interpret the results.
As metabolomics is becoming more widely used as an experimental approach, researchers need to
learn how to interpret the metabolomic data. To aid this, developers of bioinformatic tools have
been building environments, in which a layman can perform advanced statistical analyses with
guidance for using methods and interpreting results. Notable such environments are e.g. XCMS
(Tautenhahn et al. 2012, Gowda et al. 2014), and MetaboAnalyst (Xia et al. 2009), the latter of
which has been used in this study. XCSM is designed particularly for untargeted metabolomics,
and MetaboAnalyst can be used for both targeted and untargeted data. Below, key points about
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some common tools for metabolomic analysis are explored and explained, namely what a specific
tool does and how it works.
3.4.1 Preprocessing and outlier removal
Preprocessing is a mechanical step in the analysis pipeline, preparing the data for subsequent
analysis. Certain unit operations have to be performed on a given set of data in order to obtain
reliable results from it. As mentioned, in untargeted metabolomics it is particularly effortful. When
the results from measurements are obtained as concentration values in targeted metabolomics, only
statistical preprocessing is needed before statistical analysis. This usually comprises normalization,
transformation, or scaling, and possibly outlier removal before these (Xia & Wishart 2016).
Multivariate methods and e.g. log-scaling cannot cope with missing values (Xi et al. 2014), which
is why these either have to be replaced, or the whole sample or feature with missing values removed
from analysis. Because of this, removal of single outlier values should be avoided. Normalisation
aims to remove or dampen unwanted noise in the data, thereby also treating possible outliers so as to
lessen their distorting effect. If outliers arise and are removed from the analysed data, normalisation
has to be redone.
It would be best if there always was an instrumental reason for outlier removal (personal commu-
nication, Sampsa Hautaniemi). In the strict sense, computational methods cannot reliably account
for outliers even though many statistical tests for outlier removal exist. A practical observation
of measurement error is the preferred justification for outlier removal. On the other hand, whole
samples are often judged as outliers based on dimension reduction models, in which they may stand
out from the rest of the sample, e.g. a single sample that shows up very far away from a cluster of
the sample group on a PCA scores plot.
3.4.2 Visualisation of the data
Most of the analysis methods produce a visual result as an outcome, and such one should be sought
after in all other cases, too. Visualisation helps the mind grasp the data. It is good to start
exploring a new data set by generating different plots of it, e.g. using simple univariate statistics.
These plots for data exploration will probably not end up in publications, but are instead a useful
tool to familiarise oneself with the data. (Chang 2013)
A useful way to get an overview and see all the data at once is to generate a heatmap of the concen-
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tration values. MetaboAnalyst offers hierarchical clustering (HC) in conjunction with heatmaps,
so that samples and metabolites are organised based on the HC dendrogram. The distance mea-
sure for HCA can be chosen between the Pearson R, Spearman rank correlation, and Kendall rank
correlation. When exploring the data, it is useful to not cluster the samples, so that trends within
and between sample groups become evident in the heatmap, when samples from the same group
are displayed next to each other (Xia & Wishart 2016). In an optimal case the HC algorithm
would judge samples from the same group as similar and place them next to each other, but this
oftentimes does not happen and hence not clustering the samples helps.
Box plots are an effective way of fitting both data values and descriptive statistics into one picture.
The ranges of the two middle and two outer quartiles of data points are depicted by the box and
its whiskers, respectively. The median is drawn as a horizontal line within the box, and outlier
candidates are drawn as individual points outside the reach of the whiskers. Box plots can easily
be drawn e.g. in R with a single function applied on values for one feature. Viewing the plots gives
insight into patterns of the values, to see which are up or down, and into the spread of values, are
they centered around the median or scattered more widely. (Chang 2013)
The more detailed positioning of values relative to the median or mean can be shown in dot plots,
where each individual value is plotted alongside a horizontal line marking the mean/median. A
variation of the box plot with an advantage similar to the dot plot is the violin plot, where the
rectangular contours of the box are replaced by a curve showing the distribution of values. Volcano
plots are useful for showing both magnitude and significance of changes in the data. Here, the
log2 of fold change (FC) is plotted over the negative log10 of the p-value. Large and significant
changes become apparent in the upper corners of the plot, along with their amount relative to all
data points. (Chang 2013)
3.4.3 Multivariate methods for dimension reduction and classification
Principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) are
multivariate analytical methods, which aim to identify features of the data that most contribute
to variation or separation (Worley & Powers 2013). They are designed to reduce the amount of
dimensions of the data while preserving information on variance. PCA is an unsupervised and
PLS-DA is a supervised method, that is, the latter algorithm uses the predefined class labels for
calculation in addition to the data itself.
PCA gives an unbiased result and it is useful for a first look at what kind of separation can be
found in the data. However, for PCA to be able to separate groups, the within-group variation has
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to be less than between-group variation (Worley & Powers 2013), which is why PLS-DA is often
used in addition or instead of PCA. In an ideal case PLS-DA could be used to verify and further
parse the clustering and loadings first observed in PCA. PCA can be used for outlier detection. An
outlier sample will be located far from other clustered samples on the scores plot (Xia & Wishart
2016).
The goodness of fit of a PLS model is given by R2 and Q2, where R2 gives the upper and Q2 the
lower limit of how well the data is explained by the model and how well the model predicts new
observations (Wold et al. 2001). In MetaboAnalyst these values are calculated in conjunction with
the cross validation and they should be checked before interpretation of the results. Because PLS
is a supervised method, it is prone to overfitting and finding separation in any set of data. An
overfitted model cannot predict observations in new measurements. The problem of overfitting is
minimised by choosing a low-dimensional model and not using excessive components for analysis
(Ebbels & Iorio 2011b).
Both tools give scores and loadings plots as results. The scores are the weights of model components
for each sample, and loadings express the weights of individual features (metabolites) in forming the
principal component. The models are multidimensional vectors, and the scores plots are two or three
dimensional projections of these vectors used for visualisation. Usually the first two components
are plotted, though it is useful to explore the model by looking at plots of different component
pairs, e.g. the second and third component. (Xia & Wishart 2016, Ebbels & Iorio 2011b)
Each score has respective loadings, and important metabolites are found by looking at the loadings
plot specific for a chosen scores plot. Metabolites which are located in the same direction as a
cluster of samples are important for the classification of those samples, e.g. a cluster with a high
score on component 1 on the scores plot is classified based on metabolites high on the loadings 1
axis. This method of interpretation is used for both PCA and PLS-DA scores and loadings plots
(Xia & Wishart 2016).
3.4.4 Machine learning in classification: Random forests
Random forests (RF) is a machine learning algorithm used for classification (Ressom et al. 2008).
In it, a large amount of decision trees is built, each tree starting with a random feature. As the trees
are then used for classification of samples from the data, they vote for the most popular class and
assign it to the sample. At each node of a tree, features are sampled with the bootstrapping method.
It can be mathematically shown that the trees always converge, which means that overfitting is not
a problem of this method (Breiman 2001).
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MetaboAnalyst offers RF for classification and for outlier sample detection. The algorithm reports
an overall out of bag (OOB) error and a plot of class error rates over the count of trees. The OOB
error is estimated based on data that is left out during tree construction (Breiman 2001). The plot
should be used for checking, after how many generated trees the class error rates become stable
and adjusting the amount of trees so that it exceeds that limit (Xia & Wishart 2016). The stable
error rate means that the value stays constant over a growing number of trees.
3.4.5 Detecting significant changes
Simple and widely used statistical tests such as ANOVA, Students’ t-test or the Wilcoxon Rank Sum
test can be applied to metabolomic data while keeping in mind, that these do not automatically
include adjustments for multiple testing. If testing is done on original unnormalised data, it is useful
to investigate the normality of the data in order to determine if a test can be used that assumes
a normal distribution (Mary-Huard & Robin 2011). In general, several different approaches to
analysis yielding similar results solidifies the results. Results from different tests can be compared
for their greater reliability.
Significance analysis of microarrays (SAM) is a statistical method that yields a list of significantly
changed features as a result, and it can be used in MetaboAnalyst. It was originally developed for
analysing microarray data (Tusher et al. 2001), but it has been adapted for use in metabolomics
(Xia & Wishart 2016). The analysis is guided by specifying a delta value that controls the FDR.
A larger delta gives a smaller FDR and a smaller amount of significantly changed metabolites.
3.4.6 Hunting for patterns
Often, patterns in the levels of metabolites in the studied groups begin to emerge in the data
analysis. Using correlation coefficients, more metabolites with the same observed concentration
pattern can be found. In MetaboAnalyst, correlation coefficients are utilised in correlation matrices
and in the PatternHunter tool (Xia & Wishart 2016). In the correlation matrices Pearson R values
calculated for all metabolite pairs are plotted on a colour scale. The metabolite rows can additionally
be organised with hierarchical clustering in the same way as in the heatmaps. Distinct areas of
high positive or negative correlation can then be looked at to see which metabolites form them.
The PatternHunter uses the same correlation coefficients as can be chosen for HCA. Here, a pattern
of concentrations can be chosen, and then searched for in the dataset. Different correlation coeffi-
cients weight attributes of the data differently, e.g. magnitude of change matters for the Pearson
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R, and direction of change for the Spearman rank correlation (Xia & Wishart 2016). To illus-
trate, high-low-high-low can be searched for with e.g. 3-1-2-1 or 2-1-2-1, where the first pattern
emphasises the value of the first compared group.
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4 Materials and methods
4.1 A cohort of mice
The FGF21 KO mice used in this study were created by PhD student Saara Forsstro¨m using the
Cre-LoxP system. Deletor mice were crossed with previously characterised PGK-Cre (Lallemand
et al. 1998), and Fgf21LoxP/LoxP (Potthoff et al. 2009) mice, resulting in the total body knock-out
of FGF21 and yielding littermates of all the four different studied genotypes presented in Table 1.
The mice were euthanised at the age of 22-24 months and their tissues were collected for subsequent
analysis. Snap frozen tissue samples of mouse quadriceps femoris (QF, skeletal muscle), gastrocne-
mius (GC, skeletal muscle), heart, liver, cerebral cortex, and dorsal and ventral hippocampi were
used for the experiments presented in this thesis.
Strain name Genotype
Deletor FGF21 KO Twinkledup+/−; PGK-Cre; FGF21flox/flox
FGF21 KO PGK-Cre; FGF21flox/flox
Deletor Twinkledup+/−
Wild type Twinkledup−/−
Table 1: The genotypes of the mice in the study.
4.2 Metabolomics
The metabolomic data set was measured by Vidya Velagapudi from QF samples with the same
method as published in Nikkanen et al. (2016).
4.2.1 Selection of analytical tools and questions to guide the analysis
In bioinformatics it is possible to generate an endless amount of results in values, tables, matrices,
lists of metabolites, all while losing sight of the underlying biology. While it is important to explore
the data in various ways, an attempt at restraining the output of analyses was made in order to
stay aware of what is relevant. Simple illustrations were drawn in R to satisfy a curiosity about
individual points. Otherwise, a subset of analytical tools in MetaboAnalyst was picked for use, as
presented in Table 4.2.1.
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Analysis was done starting from the general and searching for details that could be explored further.
To get started with data exploration, some initial questions were stated. As a reference, dot plots
of all measured metabolites were drawn with t-test results printed alongside the plots. These plots
and the tables of significances can be found in the Appendix.
Initial questions were:
Which chemical compound classes are represented? That is, which metabolites does the in-
strumental setup allow to be measured? Does this introduce bias into which metabolites are
represented?
Which metabolic pathways are represented? How do the measured compounds scatter into
metabolic pathways? By how many and which metabolites is each pathway represented?
Are there any clearly visible trends on a big heatmap of all the data? Is there enough variance
for separation of the groups with multivariate PC and PLS-D analysis?
Are the same metabolites upregulated in the Deletor as previously published? Do the altered
pathways behave in the same manner, also the enzymes involved?
Further metabolomic analysis expanded from this starting point. How do the metabolites relevant
for the Deletor behave in both the KO mice? Where does the presence or absence of FGF21 make a
difference? Do the FGF21 KO mice in WT background harbour alterations which are not observed
in Deletor FGF21 KO mice?
4.2.2 Statistical preprocessing
The metabolomic data was provided in two different forms, first as original concentration values
and second as values normalised against a reference sample as in Dieterle et al. (2006), and log-
normalised. In the analysis using R, the original measured concentration values were used. For
comparability with Nikkanen et al. (2016), outlier values were identified and removed using the
robust regression and outlier removal (ROUT) method (Q = 1%) on GraphPad Prism 6.0 as in the
article. In the analysis using MetaboAnalyst, the normalised data was used and no single outlier
values were removed.
Two different tools were used for the metabolomic analysis. Fold change calculations and the
assessment of statistical significance using Student’s t-test were performed in R in order to generate
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Method Type Format of the results
Heatmap with hierar-
chical clustering (HC)
Univariate and HC Metabolites and/or samples organised by hi-
erarchical clustering and concentration values
plotted in a matrix on a colour scale
ANOVA with a post-
hoc test: Fisher’s least
significant difference
(LSD)
Univariate p-values indicating the significance of differ-
ence between means of all genotype groups,
and group pairs between which the significant
difference is observed
Significance analysis of
microarrays (SAM)
Univariate p-values indicating statistically significant
changes within this dataset
Random forests (RF) Machine learning Strength assessment of the classification tree
forest, metabolites important for classifica-
tion, and possible outlier samples
Principal component
analysis (PCA)
Multivariate Scores and loadings plots for selected dimen-
sions of the created model
Partial least squares
discriminant analysis
(PLS-DA)
Multivariate Scores and loadings plots for selected dimen-
sions of the created model, and variable im-
portance in projection scores for the metabo-
lites
Correlation matrix
with HC
Univariate and HC Metabolites and/or samples organised by HC
and correlation coefficients between metabo-
lites plotted in a matrix on a colour scale
PatternHunter Univariate Plot of metabolites with the highest correla-
tion with the queried pattern
Table 2: Some of the analytical tools available in MetaboAnalyst which were used in this study.
Figure 1: Illustrated data transformation and scaling of original concentration values in Metabo-
Analyst. log transformation and mean centering of the Deletor and wild type genotypes.
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barplots, dot plots, and volcano plots of the data. In the barplots, the data was chosen to be
presented as fold changes with the standard error. In the dot plots, the original concentration
values, the mean, and standard deviation are shown. All of the subsequent analysis was conducted
in MetaboAnalyst. In addition to R and MetaboAnalyst, GraphPad Prism 6.0 was used only for
the one method of outlier removal.
4.2.3 Data upload and missing value treatment
In R, the data was imported as comma separated values (csv) tables and handled as data frames.
Means and fold changes were calculated, and the function ”t.test” used for unpaired Student’s t-
tests (confidence level = 0.95) to compare the metabolite concentration means between all genotype
pairs (Del/WT, Del/DelKO, KO/WT, DelKO/WT, DelKO/KO, and Del/KO).
The normalised concentration values were uploaded into MetaboAnalyst. Four missing values were
left in this dataset, all in the sample AW3400D- (in 5,10-methenyl-THF, 5-methyl-THF, THF,
and N5-formyl-THF). These were imputed by replacement with the column mean to allow for
multivariate analysis. Replacement by a small value was also tried out. There, the assumption is
that the missing concentrations were below the instrumental detection limit. This resulted in the
sample with the missing values repeatedly showing up as an outlier in the analysis. The column
mean worked better, and subsequent analysis looked reasonable.
For comparison between only a pair of genotypes at a time, the unnormalised original concentration
values for each pair were uploaded into Metaboanalyst. Metabolites with ¿50% missing values were
left out of analysis. Thereupon missing values were replaced by the column mean, and the data was
log-transformed and mean centered. The result of this treatment for the genotype pair Deletor-WT
is illustrated in Figure 1.
4.3 Detecting messenger RNA expression
qRT-PCR reactions were performed with samples from several mouse tissues to detect expression
levels of mRNA for Fgf21 and relevant enzymes. For this, total RNA was isolated from mouse liver,
GC, and heart tissue samples. Additionally, RNA samples from mouse QF, cerebral cortex, and
dorsal and ventral hippocampi isolated by the laboratory technician Tuula Manninen were used for
analysis.
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Figure 2: Total RNA isolated from gastrocnemius, heart and liver samples, with visible 18S and
28S ribosomal RNA bands.
4.3.1 Total RNA extraction
For GC, heart, and liver RNA, samples from Deletor and Deletor FGF21 KO mice were used. The
samples were homogenised in the Trizol reagent (Invitrogen # 15596026) using a Precellys tabletop
bead homogeniser for 30 s with the speed 5000. The total RNA was extracted in chloroform,
precipitated with ethanol, and resuspended in TE buffer. RNA concentrations were measured with
a NanoDrop1000 spectrophotometer.
The integrity of the isolated RNA was checked by agarose gel electrophoresis. A 1 w-% agarose gel
with ethidium bromide was prepared. The samples were run on the gel at 90 V and 100 mA. 18S
and 28S ribosomal RNA bands were observed under UV light in each sample on the gels, indicating
that the isolated RNA was intact. The gels for GC, heart, and liver RNA can be seen in Figure 2.
4.3.2 cDNA synthesis
cDNA was synthesised from 500 ng of total RNA from each sample, using the Maxima first strand
cDNA synthesis kit (ThermoScientific # K1671). Before synthesis the samples were treated with
dsDNAse from the kit to minimise DNA contamination.
After cDNA synthesis, samples were selected to spot-check once more for RNA integrity by perform-
ing a PCR. Three samples were picked, one from each extracted tissue but otherwise randomly. The
gene for mitochondrial helicase TWINKLE was selected for amplification, because for it primers
were available which were complementary to locations in exons and thus suitable for the cDNA.
The primers had been designed by PhD student Olesia Ignatenko.
cDNA corresponding to ∼13 ng total RNA was used for each reaction, along with primers presented
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Gene Forward primer Reverse primer
Phgdh gaccccatcatctctcctga gcacacctttcttgcactga
Psat1 agtggagcgccagaatagaa cttcggttgtgacagcgtta
Fgf21 ctgggggtctaccaagcata cacccaggatttgaatgacc
β-actin atgctccccgggctgtat cataggagtccttctgacccattc
Twinkle cgttttgaggacctgcctct ttggacacctgcagataccg
Table 3: All primers used for polymerase chain reactions (PCR). Phgdh = phosphoglycerate dehy-
drogenase, Psat1 = phophoserine aminotransferase, Fgf21 = fibroblast growth factor 21.
in table 4.3.3, the Phire polymerase and 10 mM dNTP:s. The PCR products were separated by
agarose gel electrophoresis on a 1.5 w-% gel. Bands of approximately the right size of 350 bp were
observed, indicating that the RNA extraction had been successful, as can be seen in Figure 3.
Figure 3: Products of the Twinkle polymerase chain reaction (PCR) from gastrocnemius, heart,
and liver samples.
4.3.3 Quantitative PCR
qRT-PCR was performed on a BioRad CFX96 Touch Real-Time PCR System using the SYBR
Green detection system. iQ SYBR Green Master mix (BioRad # 4312704), forward and reverse
primers, and cDNA sample were added into 20 µl reactions in each well. cDNA corresponding to
∼8 ng total RNA was used per well for all runs and samples were run in triplicates, except for
Fgf21. For detecting Fgf21, cDNA corresponding to ∼80 ng total RNA was used and samples were
run in duplicates. β-actin was used as the housekeeping gene control. The results were calculated
using the comparative CT method (Schmittgen & Livak 2008). All used primers are presented in
Table 4.3.3.
4.4 Detecting protein expression
The expression levels of selected proteins were measured in QF samples using western blotting.
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Type Host Anti Supplier Cat. No. Dilution
primary rabbit CTH Proteintech 12217-I-AP 1:2000
primary rabbit GCLC Proteintech 12601-1-AP 1:1000
primary chicken MTHFD2 Abcam ab37840 1:2000
primary rabbit MTHFD1L Proteintech 16113-1-AP 1:1000
secondary goat mouse Jackson ImmunoResearch 115-035-146 1:10 000
secondary goat rabbit Jackson ImmunoResearch 111-035-144 1:10 000
Table 4: Used antibodies and their dilutions. All dilutions were made with 5 % milk in tris-buffered
saline with Tween 20 (TBST), except for anti-CTH, which was diluted in 3 % bovine serum albumin
(BSA) in TBST. CTH = cystathionine gamma-lyase, GCLC = glutamate-cysteine ligase, MTHFD2
= methylene tetrahydrofolate dehydrogenase, MTHFD1L = C1-tetrahydrofolate synthase.
4.4.1 Preparation of total protein lysates
The total protein was extracted from QF samples of mice of all four studied genotypes. 20–30 mg
samples from each mouse were homogenised in TBS using the Precellys bead homogeniser at speed
2500 rpm. The samples were placed on ice for 30 s between 30 s rounds of homogenisation and
these steps were repeated until no more intact muscle tissue was visible in the tube (5–6 times). 1
% Triton-X was added to each tube. The samples were left on ice for 30 min and then spinned at
full speed at +4◦C. The supernatants were kept while discarding the pellets.
The protein concentrations of the lysates were determined using the Bradford assay (Bradford
reagent BioRad # 5000006). BSA standards diluted from a stock solution were used as reference.
The standards were reutilised from a BCA assay kit (Thermo Fisher # 23225). Sample lysates
were diluted 1:20 and 10 µl of diluted sample was added to 180 µl Bradford reagent per well on a
96 well plate and incubated for 5 minutes. The plate was read at 595 nm on a spectrophotometer
and total protein concentrations were determined based the resulting calibration curve.
4.4.2 Gel electrophoresis and immunoblotting
The total protein samples were buffered with Laemmli. 15 µg total protein was loaded into each well
of a 4–20 % gradient SDS-polyacrylamide gel (BioRad # 4568095). 10 µl of the Dual Color protein
standard (BioRad # 1610394) was loaded into one well for reference. The gel was run at 60 mV until
the bands of the standard separated and at 120 mV until completion. The separated proteins were
transferred onto a PVDF membrane using preassembled packs (BioRad # 1704156) on BioRad’s
Turbo Transfer System. The membrane was imaged BioRad’s ChemiDoc XRS+ apparatus to detect
total protein.
The membrane was blocked in 5 % milk in TBST for 1 h, followed by an overnight incubation with
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a primary antibody, and a 1 h incubation with a secondary antibody conjugated with horseradish
peroxidase (HRP). The used antibodies and their respective dilutions and solvents are listed in
Table 4. The membrane was kept under agitation at all times and washed with the antibody
solvent between steps for 3*5 min. An enhanced chemiluminescence (ECL) reagent (ClarityTM
Western ECL Substrate BioRad # 1705061) was added and the membrane was imaged again with
the ChemiDoc XRS+ to detect antibody-specific protein bands.
The western blots were quantified using ImageJ as in Miller (2010) and normalised against total
protein. For the normalisation, a uniform area not containing the protein of interest was selected
in the imaged stain-free gel showing total protein. The areas used for normalisation of each blot
are shown in Figure 13 alongside the Western Blot results. Though the results were quantified,
statistics were not calculated because only three samples of each genotype were measured.
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5 Results
5.1 Verification of the knock-out
Expression levels of Fgf21 mRNA were measured in a panel of tissues from Deletor and Deletor
FGF21 KO mice in order to ascertain that the global knock-out of FGF21 had been successful.
cDNA from samples of GC, heart, liver, cerebral cortex, and dorsal and ventral hippocampi were
used.
In all of the brain samples, Fgf21 was not detected. GC, heart, and liver showed very low expression
in the Deletors but not in the Deletor FGF21 KO tissues. A Deletor QF positive control showed
clear expression 10 cycles earlier than the Deletor GC, heart, and liver samples.
Because most of the experiments had a negative result and any expression was only detected at very
late PCR cycles, the results are not presented quantified and as a graph. The essential results are:
first, that the knock-out of FGF21 had been successful and second, that low expression of Fgf21 in
the Deletor GC muscle exists.
5.2 A rough large scale pattern in metabolite levels
A heatmap of all concentration values in the data set, as measured by our collaborator Vidya
Velagapudi, was generated and can be seen in Figure 4. The metabolites were organised using
hierarchical clustering with the Pearson R coefficient as the distance measure and Ward as the
clustering algorithm. Care was taken not to cluster the samples and instead keep the groups intact,
so that possible trends specific for genotype would become apparent.
A rough general pattern to metabolite concentration values can be seen in the heatmap, when the
lower large branch of the hierarchical clustering tree is scrutinised. In this subset of metabolites,
Deletors have high concentration values and FGF21 KO mice have low ones. Deletor FGF21 KO
mice settle in between the former two and WT mice have variable values.
No obvious outlier samples are observed. Many of the low data values are found to be concentrated
into single samples (e.g. BSF34D- and AW3360D+), even though the data has been thoroughly
normalised. One sample has a set of noticeably high metabolite concentrations (SF324D-). None
of these samples is aberrant enough for confident classification as an outlier.
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Figure 4: A heatmap of the concentration values of all analysed metabolites.
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Figure 5: Principal component analysis (PCA). (Left) The scores plot of the first two principal
components and (right) the corresponding loadings plot.
5.3 No separation of the genotypes using multivariate methods
5.3.1 Analysis of all genotypes together
The PCA scores plot of the first two principal components does not show definitive separation
between any of the groups, as can be seen in Figure 5. An imprecise separation can be observed
on the up-left to down-right diagonal axis in the plot. Based on the observation of this axis and
the loadings plot respective to the scores plot, a group of carnitines could be important for the
Deletor FGF21 KO phenotype (the arachidyl, stearoyl, dodecanoyl, tetradecanoyl and palmitoyl
carnitines). Accordingly, N5-formyl-THF, hippurate, and 4-pyridoxate are probably important for
the WT and FGF21 KO phenotypes.
Similar to the PCA, there is no clear separation of the groups in PLS-DA (Figure 6). Again,
hippurate and 4-pyridoxate might be important for the FGF21 KO and WT phenotypes. In the
respective loadings plot, a cluster of carnitines appears again, this time together with xanthine
and 1-methylhistamine, all of which have thus similar loading scores. The fifteen most important
metabolites in forming this PLS-DA model are listed in Figure A2. The three most important ones,
hippurate, 4-pyridoxate, and N5-formyl-THF also attracted attention in the loadings plots for both
PLS-DA and PCA.
Cross validation and permutation test scores for the PLS-D model can be seen in the Appendix in
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Figure 6: Partial least squares discriminant analysis (PLS-DA). (Left) The scores plot of the first
two components and (right) the corresponding loadings plot.
Figure A1. Based on the cross validation, the two component model is most optimal for this data
set, even though its Q-value is negative, which indicates a bad fit. The permutation test gives a
p-value of 0.13 for the prediction accuracy of the model (2000 permutations). The cross validation
and permutation test together indicate, that the PLS-D model is not strong. Based on this analysis,
there is no clear large scale or global difference between all the four genotype groups when they are
analysed together.
5.3.2 Pairwise comparison of genotypes
PCA could not classify genotype groups when only two genotypes were analysed at a time. PLS-
DA could, but the differences indicated by loadings plots were in metabolites that did not give any
coherent further information, as discussed later in more detail.
5.4 Specific metabolic changes differ between genotypes
The three analytical methods SAM (significance analysis of microarrays), ANOVA, and RF together
pintpoint eight metabolites, which provide separation between the genotypes in this study. All
seven of these metabolites are closely related to the one carbon cycle metabolic pathway, implying
that FGF21 modifies 1C metabolism. Below, the analysis leading to these specific metabolites is
presented.
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Figure 7: (Left) Significance analysis of microarrays (SAM) with the false discovery rate (FDR)
controlled by a strict delta = 3. The analysis gives 7 significant metabolites, out of which 0.18 could
be false with the FDR 0.014. (Right) RF error rate calculations. Overall and class error rates are
plotted over the number of generated classification trees.
5.4.1 Filtering out eight interesting metabolites
In the SAM analysis, different delta values for controlling the false discovery rate (FDR) were
tried out. The strictest obtained result was with delta = 3, where the seven metabolites succinate,
glutamate, betaine, phosphoethanolamine, deoxyuridine, creatine and guanidinoacetate were found
to be significantly changed with a FDR of 0.18, as can be seen in Figure 7.
One-way ANOVA with Fisher’s LSD post-hoc tests was performed. 32 metabolites had a p-value
<0.05, meaning that in these metabolite hits there is at least one genotype group pair which differs
with that level of significance. The post-hoc test reveals the group pairs in which the difference is
observed. The seven highest ranking metabolites completely coincide with the results from SAM,
as presented in the summary in Table 5.4.1. The 15 most significant metabolites from the ANOVA
analysis and their respective pairs with significant changes are listed in the Appendix in Table A1.
The random forest (RF) algorithm was run with the parameters ”2000 trees” and ”7 predictors per
node”. Important metabolites based on this analysis are listed in Table 5.4.1 alongside ANOVA
and SAM values, and also in Figure A2 next to metabolites important in the PLS-D model. As
can be seen in both figure and table, the important metabolites based on PLS-DA and RF do for
the most part not agree. Deoxyuridine, glutamate, and cytosine come up in both analyses.
26
ANOVA p-value SAM raw p RF MDA PLS-DA VIP
1 Succinate 0.0005 Succinate 0.0005 Succinate 0.011 Hippurate 3.7
2 Glutamate 0.0009 Glutamate 0.0009 Creatine 0.009 4-Pyridoxate 3.2
3 Betaine 0.0014 Betaine 0.0013 Deoxyuridine 0.009 N5-Formyl-THF 2.4
4 PE 0.0015 PE 0.0013 Threonine 0.009 Adenosine 2.3
5 Deoxyuridine 0.0018 Deoxyuridine 0.0016 Betaine 0.008 Lysine 2.2
6 Creatine 0.0019 Creatine 0.0017 Glutamate 0.008 Guanosine 2.2
7 GAA 0.0021 GAA 0.0020 PE 0.006 Choline 2.2
Table 5: Comparison of metabolite hits. ANOVA = analysis of variance, SAM = significance
analysis of microarrays, RF = random forests, PLS-DA = partial least squares discriminant anal-
ysis, MDA = mean decrease accuracy, VIP = variable importance in projection, PE = phospho-
ethanolamine, GAA = guanidinoacetate, THF = tetrahydrofolate.
The error values and the corresponding stabilisation plot for the algorithm can be seen in Figure 7.
An OOB overall error rate of 0.5 was reported, which is quite high. The FGF21 KO group had the
lowest class error rate of 0.25, which became stable already at around 600 trees, whereas the WT
group had a very high class error rate of 0.75, which did not fully stabilise even after 2000 trees.
The Deletor and Deletor FGF21 KO groups had error rates of 0.5, conforming with the overall
OOB error rate. Based on these error values, there is most variation between samples in the WT
group and least in the FGF21 KO group.
5.4.2 Observed patterns reflect known upregulation in the Deletor
The top seven metabolites from SAM and ANOVA coincide completely, and RF nearly equally,
adding only threonine to the list as seen in Table 5.4.1. These eight metabolites are shown in Figure
8 in dot plots. To complement the three statistical methods already used, significances between
genotypes are shown as determined by Student’s t-test. All of these metabolites are closely related
to 1C metabolism.
Glutamate, betaine, phosphoethanolamine, and threonine act in a similar way: they have elevated
levels in the Deletor, which are rescued by the knock-out of FGF21. Choline and acetylcarnitine
share their concentration pattern with these three, and they are shown in Figure 5.4.2. Deoxyuridine
acts unlike all other metabolites in that it has elevated levels in all genotypes but the wild type.
Removal of FGF21 leads to elevated levels of deoxyuridine.
Finally, succinate, guanidoacetate, and creatine have low levels in the FGF21 knock-out mice with-
out the Deletor mutation. This implicates, that the Deletor pathomechanism keeps these metabo-
lites from decreasing in the Deletor FGF21-KO mice. Metabolic changes in the Deletor in general
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include high levels of metabolites, so presumably high levels of other metabolites in the intertwined
metabolic network keep these three from lowering in the Deletor FGF21-KO.
5.5 Fibroblast growth factor 21 adds to the disease progression
As already seen in the individual metabolites glutamate, betaine, phosphoethanolamine, and thre-
onine, aspects of the pathology in the Deletor tend to be rescued by the knock-out of FGF21. This
is discovered further in another look at the metabolomic data, and in expression levels of specific
enzymes as examined by mRNA and protein measurements.
5.5.1 Upregulated metabolites tend to be rescued
To illustrate significantly changed metabolites, bar plots, volcano plots, and dot plots were drawn
in R. These illustrations were generated from the unnormalised but outlier-removed data, and
significances were determined using Student’s t-test.
Of these, a plot depicting upregulated metabolites in the Deletor revealed their consistent depen-
dence on FGF21 (Figure 10). Here, all significantly changed metabolites of the Deletor compared
to WT were plotted as fold changes, and the same metabolites picked from the Deletor FGF21 KO
data for comparison, again fold changes compared to WT. Strikingly, most of these metabolites
returned to WT levels in the Deletor FGF21 KO mice, implying that removal of FGF21 rescues
part of the phenotype in the Deletor.
In the volcano plots in Figure 11 the plot of the Deletor shows mostly upregulated metabolites
and the FGF21 KO mostly downregulated metabolites, which is the same rough large scale pattern
as observed in the heatmap in Figure 4. The significantly changed metabolites in the Deletor
FGF21 KO are mostly not the same as in the Deletor, which is natural, given the rescue observed
above. This does however point out, that the removal of FGF21 causes also other effects than solely
rescuing the upregulation of metabolites in the Deletor.
5.5.2 Corresponding changes on enzyme and metabolite levels
The serine pathway channels glucose carbon units into 1C metabolism and it has been shown to
be upregulated in mitochondrial myopathy in the Deletor and in human patients (Tyynismaa et al.
2010, Nikkanen et al. 2016). Elevated glucose uptake into the diseased Deletor muscle feeds serine
into the folate cycle, where one carbon units are converted into formate and used for methylation
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Figure 8: Dot plots of selected metabolites, which frequently turn up in the analysis. The signifi-
cances between each pair of groups were determined by Student’s t-test. * = p < 0.05, ** = p <
0.01, *** = p < 0.001.
29
Choline
0
5
10
15
umol/g
WT
FG
F2
1 K
O
De
let
or
De
l F
GF
21
 KO
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
*
Acetylcarnitine
0
10
20
30
40
umol/g
WT
FG
F2
1 K
O
De
let
or
De
l F
GF
21
 KO
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
ll
l
l
l
l
l l
l
l
*
*
**
Figure 9: Choline and acetylcarnitine levels shown as dot plots. The significances were determined
by Student’s t-test, * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
reactions, and into the transsulfuration pathway that produces glutathione. Out of these pathways,
enzymes shown to be upregulated in the Deletor were selected for study to see if removal of FGF21
has an effect on them. As on the metabolite level, FGF21 drives the upregulation of part of the
studied metabolic pathways on the enzyme level.
The mRNA expression of two enzymes from the serine de novo synthesis pathway were measured
in all four genotypes. These were D-3-phophoglycerate dehydrogenase (Phgdh) and phosphoserine
aminotransferase (Psat1 ), both of which are upregulated in the Deletor (Tyynismaa et al. 2010,
Nikkanen et al. 2016). The results are shown in Figure 12. The expression of both enzymes was
high in the Deletor and both were brought down in the absence of FGF21. In Phgdh the effect was
evident in both WT and Deletor backgrounds.
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Figure 10: All metabolites that are changed significantly in the Deletor compared to WT, and
the same metabolites in the Deletor FGF21 KO. Fold changes of both genotypes were calculated
compared to WT. The significances between groups were determined by Student’s t-test. * = p <
0.05, ** = p < 0.01, *** = p < 0.001
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Figure 11: Volcano plots. (Up-left) Deletor vs WT. (Up-right) Deletor FGF21 KO vs WT. (Down-
left) Deletor FGF21 KO vs Del. (Down-right) FGF21 KO vs WT. The rough pattern seen in the
global heatmap repeats itself in the volcano plots: the Deletor has mostly high levels of metabolites
and the FGF21 KO mostly low levels of metabolites. It can also be seen, that the significantly
changed metabolites in the Deletor FGF21 KO are mostly not the same as in the Deletor.
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Figure 13: Western blots along with the total protein area used for quantitation. Expression
in skeletal muscle. (Up-left) MTHFD2 = methylene tetrahydrofolate dehydrogenase. (Up-right)
CTH = cystathionine gamma-lyase. (Down-left) GCLC = glutamate-cysteine ligase. (Down-right)
MTHFD1L = C1-tetrahydrofolate synthase.
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Figure 12: qRT-PCR in QF skeletal muscle. Data presented as fold change compared to WT.
Psat1 = phosphoserine aminotransferase, Phgdh = D-3-phosphoglycerate dehydrogenase. The sig-
nificances between each pair of groups were determined by Student’s t-test. * = p < 0.05, ** = p
< 0.01, *** = p < 0.001
The enzymes Methylene tetrahydrofolate dehydrogenase (MTHFD2), C1-tetrahydrofolate synthase
(MTHFD1L), cystathionine gamma-lyase (CTH) and glutamate-cysteine ligase (GCLC) were stud-
ied by western blotting (Figure 13). MTHFD2 and MTHFD1L catalyse the interconversion of folate
intermediates in the folate cycle. CTH and GCLC are enzymes of the transsulfuration pathway.
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GCLC is upregulated in FGF21 KO mice compared to the other genotypes. The upregulation in
the Deletor is not replicated in a clear manner. The enzyme catalyses the synthesis of gamma-
glutamylcysteine out of glutamate and cysteine. The respective metabolites were not found to be
altered, except for the upregulation of glutamate in the Deletor. The metabolite measurement for
gamma-glutamylcysteine had very low precision. It is difficult to draw conclusions regarding the
enzyme GCLC in this context.
CTH and MTHFD1L expression return to WT levels in Deletor FGF21 KO mice. MTHFD2 is
slightly less highly expressed in Deletor FGF21 KO mice than in Deletors based on the quantitations
of the blots (Figure 14), but essentially it is not regulated by FGF21 based on this result.
Figure 14: Western blot quantitations. (Up-left) MTHFD2 = methylene tetrahydrofolate dehydro-
genase. (Up-right) CTH = cystathionine gamma-lyase. (Down-left) GCLC = glutamate-cysteine
ligase. (Down-right) MTHFD1L = C1-tetrahydrofolate synthase. No statistics were calculated
because the number of samples per group was only three.
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5.6 Long-chain acylcarnitines are not affected
Acylcarnitines were analysed, because they have high levels in PEO patient muscle (Nikkanen et al.
2016). The results of this KO study indicate, that long-chain acylcarnitines are not regulated by
FGF21, as can be seen in the heatmaps of the top 25 metabolites from the ANOVA and RF analyses
are shown in Figure 15. These subsets of metabolites follow the trends observed above. Deletors
tend to have increased concentration values, and FGF21 KO mice tend to have low concentration
values. WT and Deletor FGF21 KO mice settle in between these extremes.
Their concentrations seem to act approximately in concert in all of the different genotypes, and the
hierarchical clustering algorithm has accordingly placed these metabolites closeby each other. The
acylcarnitines are high in both the Deletor and Deletor FGF21 KO mice, and low in the other two
groups, thus unaffected by the KO of FGF21 so their upregulation is caused by something other
than FGF21 in the disease mechanism. It is possible that these compounds stand out because their
class is well represented in the data set. Other compounds in the heatmaps in Figure 15 represent
various different metabolic pathways.
Figure 15: Heatmaps of the top 25 metabolites from (left) ANOVA and (right) RF analysis. The
metabolites are organised using hierarchical clustering.
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6 Discussion
The results of this study comprise that FGF21 drives some but not all of the alterations on mRNA,
protein, and metabolite levels in mitochondrial myopathy as seen in the Deletor. FGF21 does this in
a widespread manner, while still not being the only driving force in the disease. It also plays a role in
normal physiology, as revealed by changes in the FGF21 KO metabolite levels. The alterations seen
in this study revolve around closely related pathways to such extent that most altered metabolites
and some enzymes could be illustrated in compact form in the cartoon in Figure 16.
FGF21 is expressed in a variety of tissues, has a large variety of actions and is induced via many
different signals. Its numerous functions are reflected by the fact that its removal caused many
alterations in the KO mice of this study. The identified alterations can be grouped under larger
themes as follows. Alongside these points on physiology some technical aspects on metabolomics
are discussed.
6.1 Physiology
6.1.1 Regulatory hierarchy
The physiology of FGF21 is complex, as is reviewed from a general viewpoint in Fischer & Marator-
Flier (2016), and from a viewpoint of stress signalling in Salminen et al. (2017). To illustrate this
statement, it was recently established that mTORC1 regulates FGF21 (Khan et al. 2017), and that
FGF21 contributes to mTORC1 activation (Minard et al. 2016). It is also known, that ATF-group
transcription factors regulate transcription of AARE genes, among them FGF21 (Tyynismaa et al.
2010), but the study in this thesis shows that FGF21 also regulates transcription of genes that seem
to be under AARE influence (Phgdh and Psat1 ).
An essential finding in this study is a generalisation of that last point. In the signalling direction
mTOR1 – ATF4 – FGF21, the hormone forms its own feed-back regulatory step in the tissue in
an autocrine manner, influencing the expression of its peer genes under promoters with AARE
sequences.
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Figure 16: A cartoon that summarises the essential results from this study and shows the featured
metabolites and enzymes in a metabolic pathway context. In green are metabolites and enzymes
in which removal of FGF21 caused an effect in this study. Above: metabolic pathways from Mus
musculus (Mouse). Not all results of this study are depicted here. Below: caricatured graphs of
interesting results. See the Results-section for the respective accurate graphs. Genotypes are always
in the order WT - FGF21 KO - Deletor - Deletor FGF21 KO. The enzymes listed in the graphs below
on the left are GCLC = glutamate-cysteine ligase, CTH = cystathionine gamma-lyase, PHGDH
= D-3-phosphoglycerate dehydrogenase, PSAT1 = phosphoserine aminotransferase, MTHFD2 =
methylene tetrahydrofolate dehydrogenase, and MTHFD1L = C1-tetrahydrofolate synthase. Other
enzymes mentioned in the pathways above catalyse the converting reactions between the respective
depicted metabolites.
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6.1.2 One carbon metabolism - carbon donors
The perhaps most essential finding of this study is that FGF21 drives the compensatory upreg-
ulation of alternative 1C donors in the face of the impaired formate production in mitochondrial
myopathy2002. Low formate production concurs with mitochondrial dysfunction as reported in Bao
et al. (2016), Nikkanen et al. (2016). In the diseased tissue there is an attempt to balance impaired
formate production by upregulation of serine de novo synthesis genes via ATF4. The alternative
carbon donors upregulated by FGF21 in the Deletor found in this study are choline, betaine, and
threonine, which can be seen in the cartoon in Figure 16. Threonine feeds into 1C metabolism
in mice, where it is converted by threonine 3-dehydrogenase (TDH) to amino ketobutyrate and
by 2-amino-3-ketobutyrate coenzyme A ligase (GCAT) into glycine. TDH is inactive in humans
(Edgar 2002).
The shuﬄing of 1C units is mediated by the folate cycle. The impact of the knock-out of FGF21
on folate cycle intermediates did not yield many tangible results. The measured folate cycle inter-
mediates are illustrated in Figure A3 in the Appendix. The upregulation of these intermediates
as reported in Nikkanen et al. (2016) was mostly not replicated. The only differences are in N5-
formyl-THF, where the Deletor FGF21 KO has notably low levels of the metabolite. Most of the
measurement points for this metabolite were spread out with low accuracy, and it is easiest to
explain the result as an unsuccessful measurement.
Based on the western blot analysis, the folate cycle enzyme MTHFD2 that is strongly upregulated
in the Deletor, supporting previously published results. Its expression did not change with the KO,
so it probably is not controlled by FGF21 but instead independently of it. The enzyme is often
seen upregulated in cancers (Nilsson et al. 2014), so there must be some strong mechanisms related
to growth and proliferation in which it is involved, which are outside of the influence of FGF21.
Choline, serine, and glycine are quantitatively the most important dietary sources of 1C units for
the folate cycle (Ducker & Rabinowitz 2017). Based on Student’s t-test choline is also significantly
high in the Deletor (Figure 5.4.2) and has the same rescue pattern as glutamate, betaine, PE, and
threonine, so it was added to the cartoon in Figure 16 alongside the other essential metabolite hits.
It would have been interesting to see whether FGF21 also influences the levels of serine and glycine,
but the upregulation of these was not replicated in the metabolomic measurement of this study and
differences between genotypes were not seen.
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6.1.3 Deoxyuridine and amino acids
1C metabolism supports the biosynthesis of purines and thymidine. Deoxyuridine is a thymidine
precursor. In this study it behaved unlike most metabolites in that it was upregulated in all three
groups, even higher in the Deletor FGF21 KO than in the other two. The change in the Deletor
FGF21 KO was significant in the post-hoc test of ANOVA, and had a p-value of 0.06 in the t-test.
These results implicate that FGF21 always acts to keep deoxyuridine levels low, which is emphasised
in the myopathy, because the disease state seems to drive the levels higher.
Amino acids have generally been reported high in the Deletor (Ahola-Erkkila¨ et al. 2010, Tyynismaa
et al. 2010, Nikkanen et al. 2016). FGF21 seems to not play a role in this tendency. Glutamate
and threonine levels did change with the knock-out, but to pick an example, asparagine dit not.
Asparagine synthetase (ASNS) is one of the proteins upregulated in the Deletor by the same AARE
as FGF21 (Tyynismaa et al. 2010). Here, the amino acid was significantly upregulated in the
Deletor FGF21 KO with a FC of 1.5 (non-significant in the Deletor, FC 1.3), which conforms with
the regulation of ASNS commencing independently of FGF21.
Glutamate has been shown to accumulate within the mitochondrial matrix in mitochondrial dys-
function of different causational origins (Chen et al. 2016). The fact that the FGF21 deletion in
this study rescued glutamate levels in particular further points in the direction tha FGF21 is an
essential part of the Deletor pathomechanism.
6.1.4 Creatine synthesis and energy metabolism
Creatine, guanidinoacetate, and succinate levels were significantly decreased in the FGF21 KO
samples compared to all other groups, as illustrated by the dot plots in Figure 8 and the cartoon
in Figure 16. Also ornithine and arginine levels were decreased in the FGF21 KO as can be seen
in dot plots in the Appendix (dot plots in alphabetical order by metabolite name). The Deletor
pathomechanism has shifted its metabolism in such a way that keeps these three metabolites at
WT levels in the Deletor FGF21 KO, whereas in the absence of FGF21 in the FGF21 KO their
levels decrease. FGF21 does not affect creatine synthesis pathway.
Creatine synthesis from utilises glycine and 1C units. Guanidinoacetate is synthesised from arginine
and glycine, releasing ornithine. GAA is then methylated to produce creatine. Based on the result
that MTHFD2 stays upregulated in the Deletor FGF21 KO, the folate cycle is upregulated at least
partly independently of FGF21. This would explain the fact that the KO does not lower creatine
and GAA levels in the Deletor FGF21 KO in that sufficient methylation capacity exists to keep
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their levels seemingly normal.
The short review by Ostojic (2015) speculates on the possibility that GAA could serve as an alter-
native energy donor when there is a lack of creatine. GAA is the direct precursor for creatine. The
downregulation of creatine and guanidoacetate in the FGF21 KO suggests, that these compounds
make up a further niche of energy metabolism in which FGF21 is involved as a hormone. Also,
all of these compounds stay high in the Deletor FGF21 KO compared to the FGF21 KO. Could
the Deletor utilise creatine phosphate more than normal as an energy source to compensate for
defective oxidative phosphorylation in skeletal muscle?
The reason for prevented lowering of succinate in the Deletor FGF21 KO compared to the sim-
ple FGF21 KO mouse could lie in the OXPHOS itself. The NADH/NAD+ ratio increases when
OXPHOS is defective, as reviewed in (Nunnari & Suomalainen 2012), and intuitively TCA cycle
intermediates could accumulate in a similar way. The review Smeitnik et al. (2006) concludes that
TCA intermediates should accumulate in tissues and body fluids and cites Esteitie et al. (2005),
which shows that TCA cycle intermediates are increased in the urine of patients with mitochondrial
disease. Beside being part of the TCA, succinate is also an epigenetic marker (Zhang et al. 2010).
The fluctuation of its levels could influence protein activity or signalling pathways, which adds yet
another level of complexity to the actions of FGF21.
Creatine and succinate have been studied as drug candidates for mitochondrial diseases in clinical
trials. The study on succinate was a case report (Shoffner et al. 1989) with a positive outcome.
The patient had a severe respiratory complex I deficiency, and combined succinate and coenzyme
Q supplementation was administered to her. The goal of the treatment was to bypass complex I in
the respiratory chain to keep oxidative phosphorylation working, and the treatment succeeded in
keeping the patient stable. Creatine supplementation was tried in several studies with variable but
mostly negative outcome (Pfeffer et al. 2013). The fact that levels of these compounds are sustained
in the mitohondrial myopathy of Deletor mice would match with unfruitful supplementation for
treatment of patients. The case report concerning treatment with succinate described above was
extreme, and partially intact OXPHOS is always better than no respiration at all.
6.1.5 On metabolic inflexibility
As a compound class, the acylcarnitines constantly attract attention in the Deletor, where they
accumulate in skeletal muscle (Khan et al. 2017). This study shows that their accumulation is
independent of FGF21. Long chain acyl carnitines can be seen grouped together in heatmaps for
the top 25 significant metabolites from ANOVA and RF in Figure 15, where they are high in
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the Deletor and Deletor FGF21 KO. ANOVA and its post-hoc test judged the pattern significant
as significant all but hexanoyl and decanoyl carnitine. Accumulating acylcarnitines are seen in
conjunction with glucose intolerance (Koves et al. 2008). Glucose intolerance is associated with
metabolic inflexibility (Muoio 2014, Goodpaster & Sparks 2017). Metabolic flexibility is the ability
of an organism to adapt its metabolism according to demand, in response to e.g. energy expenditure
or outside conditions.
In the Deletor, affected muscle tissues have increased glucose uptake (Nikkanen et al. 2016). PEO
patients are glycolytic, and in a clinical trial their diseased muscle fibres could not tolerate a
ketogenic diet (Ahola et al. 2016). In a recent review, Goodpaster & Sparks (2017) speculate on
the possibility that insulin resistance might be an adaptive response to excess glucose entering and
stored in muscle cells in the absence of increased energy expenditure. No abnormalities were found
in glucose and insulin tolerance tests of Deletors (Tyynismaa et al. 2010). Pereira et al. (2017) state
that insulin resistance is a feature seen in mitochondrial diseases and go on to show that FGF21
rescues the developing insulin resistance in OPA1-deficient mice.
Acetylcarnitine is an interesting metabolite with respect to insulin sensitivity. The carnitine acetyl-
transferase has been found to promote glucose tolerance and insulin action (Muoio et al. 2012). The
retention of acetylcarnitine at WT levels in the Deletor FGF21 KO fits well into this picture on
insulin action. The upregulation of acetylcarnitine in the disease could be an example of beneficial
FGF21 action in the myopathy. Measured acetylcarnitine levels are shown in the dot plot in Figure
5.4.2.
It is an interesting point of view to consider the disease state in terms of metabolic inflexibility.
Knowing that in mitochondrial diseases the OXPHOS is compromised by definition, this can be seen
as superfluous, but the accumulation of acyl carnitines is found to be a stress marker for metabolic
diseases, related to diabetes and obesity (Seiler et al. 2014, Noland et al. 2009). Comparing these
categories of metabolic disease might highlight possible parallel lines in disease mechanism.
6.2 Technical aspects on metabolomics
6.2.1 Group classification
PCA and PLS-DA were tried out for group classification, but these methods could not separate
the four genotypes. When all four groups were analysed together, the explained percentage of
variation was about 30-40% in both analyses, which does not convince to draw definitive conclusions.
Expecting a few principal components to be able to summarise shifts in a complex metabolic network
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is probably wishful thinking, but these multivariate tools are widely used and consequently they
were explored also in this study.
The highest variation in the data these methods could pinpoint did not lead further in the analysis.
Because of this and because the PLS-DA model was not plausible as shown by cross validation and
permutation analysis, illustrated in the Appendix in Figure A1, results from PCA and PLS-DA
were disregarded in the course of analysis. As an example, the two metabolites with the highest
VIP score in PLS-DA for all four genotype groups were hippurate and 4-pyridoxate. Looking at an
illustration of their levels, e.g. the heatmap of all metabolites in Figure 4, these two had very high
concentration values in two WT samples, and otherwise no pattern. According to both the t-test
and ANOVA these two metabolites had no changes with p <0.05 between any genotypes.
The difficulty in classification also has to do with the assessment of whether or not it is a meaningful
question to compare these particular four genotypes all together at the same time. It is indeed more
sensible to compare individual genotypes in this case, because e.g. the relationship of the FGF21
KO to the Deletor is not trivial. Nonetheless, comparison of individual genotype pairs using the
multivariate methods PCA and PLS-DA also did not yield meaningful insights. Differences between
genotype pairs could however be discerned using other methods tha PCA and PLS-DA, as was done
e.g. for the Deletor versus the Deletor FGF21 KO in Figure 10.
As an example of unfruitful pairwise classification attempts using PCA and PLS-DA, see Figure
17 for the comparison of Deletor and Deletor FGF21 KO genotypes. PCA could not separate the
groups, although it points out N5-formyl-THF in the loadings plot. The supervised method PLS-
DA neatly shows separation, but the only metabolite it uses is again N5-formyl-THF. Looking at
all measured folate intermediates in this data set as depicted in Figure A3 in the Appendix, this
particular folate metabolite does not conform with the levels of other folates in this metabolomic
set. It also had a missing value that was imputed. No conclusions concerning the folate cycle could
be drawn based on this result.
6.2.2 Previouly published results not replicated exactly
Homogeneity of the data set hampered with both analysis using multivariate methods and repli-
cation of previous results. Most of the metabolite level alterations previously reported in Deletors
(Nikkanen et al. 2016) were not reproduced in the Deletors of this study, as is shown in Table 6.
Here, all metabolites reported as significantly changed (all of them upregulated, with p <0.05 based
on Student’s t-test) were listed and respective results from this study were compared to them. With
a large set of measurements, it is to be expected that variance is observed (Bender & Lange 2001),
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Figure 17: Comparison between the Deletor and Deletor FGF21 KO using multivariate methods
of group classification. Above: A principal component analysis (PCA) scores plot of the first
two principal components and the corresponding loadings plot. Below: A partial least squares
discriminant analysis (PLS-DA) scores plot of the first two components and the corresponding
loadings plot.
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especially of metabolites which have quicly fluctuating levels. Still, the upregulation of serine and
glycine which are essential for the Deletor phenotype were not seen here.
Instead, e.g. in all of the pairwise comparisons using PCA and PLS-DA, the main differences
between mouse groups in this study as pointed out by loadings plots were made by metabolites
with concentration values that were spread out with low accuracy, e.g. hippurate, 4-pyridoxate,
N5-formyl-THF, or guanosine. Also the OOB error rate of the RF classification in this study was
0.5, which is very high compared to the MetaboAnalyst example data error rate in RF, which was
0.154 (Xia & Wishart 2016).
Thankfully, e.g. ANOVA listed significant changes in 32 metabolites so the issue is not that there
was not any variation in the data. Insight into the changes had to be sought elsewhere than from
PCA, PLS-DA, or direct comparison with data from Nikkanen et al. (2016).
6.2.3 Missing values and outliers
The fact that missing value imputation can have a large effect on statistical analysis (Armitage
et al. 2015), was seen in this study. The four missing values for the sample AW3400D- were at first
imputed by a small positive value: half of the minimum detected value. This method of imputation
is designed for the case where concentrations cannot be measured because they are below the lowest
instrumental detection limit, as is often the case for metabolites. Clearly this was not the case for
these particular metabolites, because the imputed low values stood out to such extent, that the
sample looked like an extreme outlier on PCA plots.
The error was noticed when comparing the global heatmap with the table of original concentration
values. Changing the imputation method to replacement by column mean clarified the at first
problematic clustering, and subsequent analysis did not implicate any further difficulty with this
particular sample.
The RF algorithm can also be used for outlier detection. Possible outliers suggested by RF are
depicted in in Figure 18. Highest among these was the sample SF324D-, which attracted attention
as a possible outlier also in other experiments done on the QF tissue of that individual mouse.
Because several samples had similar scores, and none of them stood out, no outliers were removed
based on the RF analysis or for any other reason, except in t-tests for comparability with Nikkanen
et al. (2016) as described in the Methods Section.
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Pathway Reported as upregulated replicated with p<0.05? FC
Folate cycle 5-methyl-THF yes 1.42
5-methylene-THF - -
formate - -
glycine no 1.47
serine no 1.19
THF no 1.01
Amino acids alanine no 1.01
asparagine no 1.31
aspartate no 1.26
glutamic acid yes 1.90
glutamine no 1.35
homoserine - -
hydroxyproline - -
isoleucine no 1.12
leucine no 1.13
phenylalanine no 1.09
proline no 1.27
threonine yes 1.27
valine no 1.19
Methyl cycle guanidinoacetic acid no 1.12
methionine no 1.17
Purine synthesis hypoxanthine no 0.86
5-hydroxyindole-3-acetic acid - -
betaine yes 1.60
choline yes 1.82
creatine no 1.01
creatinine no 1.14
GABA - -
glutathione no 0.90
glyceraldehyde no 1.10
neopterin no 1.05
niacinamide yes 1.31
phosphoethanolamine yes 1.46
taurine no 1.13
Table 6: All significantly changed metabolites in Deletor QF from Nikkanen et al. (2016) and
whether the results are replicated in this study. The referred p-values were determined by t-test.
Metabolites which were not measured in this data set are also listed.
45
-1
0
1
2
3
Samples
O
ut
ly
in
g 
M
ea
su
re
s AW3358D
SF331D-
SF324D-
SF333D
AW3344D-
Del
FGF21 KO
FGF21 KO Del
WT
Figure 18: Outlier prediction in random forests (RF). None of the indicated samples was ultimately
removed as an outlier.
6.2.4 Further correlation analysis
The PatternHunter correlation analysis in Metaboanalyst can be used for searching for metabolites
with specific concentration patterns, where patterns are indicated by choosing arbitrary integer
numbers to describe concentration differences. In the analysis for this study, the PatternHunter
did not reveal anything about the data that had not been noticed with other methods already. It
is however a convenient way of comparison that yields insightful illustrations, and I recommend it
for use at other instances. Below is a brief description of its use in this study.
Because almost all of the significantly changed metabolites in the Deletor tend to be upregulated,
patterns were chosen to be searched for in which a metabolite is high in the Deletor and low in other
groups. The Pearson R was used for measuring correlation. The pattern numbering was chosen
so that it would be simple, but still 3 was used instead of 2 to emphasise the upregulation in the
Deletor. In the analysis the groups were arranged in the order Del - KO - DelKO - WT. The pattern
3-1-3-1 reveals, which upregulated metabolites of the Deletor are induced independently of FGF21,
since they stay up in the DelKO mice. The pattern 3-1-1-1 again reveals, which metabolites are
dependent on FGF21 induction. The results can be seen in Figure 19.
The results show, that there are fairly large groups of metabolites correlating both to the pattern of
”upregulated in the Deletor and rescued by the KO of FGF21” and ”upregulated in the Deletor and
not affected byt the KO of FGF21”. The Pearson R:s were not extremely high, but these general
trends had already been seen in the heatmaps and in the analysis of individual metabolites. As
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Figure 19: PatternHunter correlation search for patterns in metabolite levels across groups. The
genotype groups were arranged in the order Del - KO - DelKO - WT. The pattern 3-1-3-1 (left)
shows, which upregulated metabolites of the Deletor are induced independently of FGF21, since
they stay up in the DelKO mice. The pattern 3-1-1-1 (right) shows which metabolites are dependent
on FGF21 induction. The Pearson R is used for measuring correlation.
the Pearson R only reaches values of about 0.5 in this analysis, many of the metabolites are shared
between both patterns. The upregulation in the Deletor then is the main common denominator for
these other metabolites.
6.3 Future considerations and dreams
6.3.1 Biology
A simple next step that directly aligns with the concept of the study in this thesis would be to
measure this same set of metabolites in the heart tissue of the studied mice. The Deletor heart was
shown to exhibit extensive metabolic alterations that partly overlap with the QF (Nikkanen et al.
2016), and looking into the heart would doubtlessly complement the results obtained so far from
QF.
Another perspective would be to look into the compartmentalisation of metabolite levels and
metabolic changes. Chen et al. (2016) developed a method of isolating mitochondria and performing
a metabolomic experiment on this cellular compartment alone. It would be very interesting to know
something about local concentrations of metabolites in individual cellular compartments. This help
to understand e.g. cell signalling. If a metabolite acts as a signalling molecule, its concentration at
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a specific location matters. Also pathway imbalances would be revealed in more detail, deciphering
physiology and pathophysiology.
6.3.2 Experimental setup
To address the homogeneity of the metabolomic data, basic refinement of the experimental setup
might be beneficial. The number of biological replicates could be optimised. Power calculations
could be performed to estimate the required number of samples for seeing differences more clearly.
In this study, the number of samples per group varied between 6–8. Also stricter standardisation
of sample collection might be useful to look into, since small molecular metabolite levels fluctu-
ate rapidly (personal communication, Vidya Velagapudi). Both of these approaches require some
restructuring of the routines with which these experiments are performed.
In a bigger picture, standardisation of experiments makes comparison between studies possible. In-
ternational organisations like the Metabolomics Standards Initiative (MSI) or the European Com-
mission funded COSMOS Project are concentrating efforts on the standardisation of metabolomics
in general. When logging sufficient metadata and adhering to good practises, metabolomics data
can be admitted for upload into databases like MetaboLights (Haug et al. 2012). Like other omics
data, e.g. from DNA sequencing or microarray experiments, the data can then be reanalysed and
used for meta-analysis or other large studies conducted by third parties.
6.3.3 Bioinformatics
MetaboAnalyst offers even more tools, not to speak of computational possibilities beyond the
MetaboAnalyst environment, that were not used in this thesis but could be used in further studies.
To pick one possibility, gene set enrichment analysis (GSEA) is a tool for microarray data inter-
pretation developed by Subramanian et al. (2005). It was modified for use in metabolomics by Xia
& Wishart (2010) and integrated into MetaboAnalyst with the name metabolite set enrichment
analysis (MSEA). The idea behind enrichment analysis is to be able to detect widespread changes
in the searched sets while variation in individual features might be small in scale.
Enrichment analysis avoids the confusion arising from multiple testing and its adjustments for
it. Instead of obtaining lists of unreliable significances or hardly any significant changes at all, it
MSEA is designed to detect subtle changes, as long as these are widespread. Analogous to SAM,
it is an analytical tool tailored for the characteristics of ’omics data. Both were originally invented
to counter the needs of transcriptomic analysis, and were later modified for use in the younger
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metabolomic field (Xia & Wishart 2016).
A possibility for improving future studies might thus be to define metabolite sets of interest that
have been established to be of particular interest for the research topic, or that have been hypo-
thetically indicated as relevant. The predefined sets based on the KEGG database that MSEA
in MetaboAnalyst uses are often too general (e.g. ”protein synthesis”) or too narrow (only one
metabolite hit fits the set) to yield meaningful insight, but self-defined sets could be more helpful.
Measuring a larger set of metabolites would also help in producing more insightful results, but
development of the targeted metabolomics experiment is a whole field of its own.
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7 Conclusions
As an applicable biomarker FGF21 has been established a prominent feature of the pathology in
mitochondrial myopathies. When knowing nothing more about its role in these diseases except
for its robust upregulation, there are two hypothetical options for its actions. Either FGF21 is a
protective measure that the body summons to counteract the disease, or it is part of the disease
driving pathophysiology.
The FGF21 KO project using Deletor mice investigates this. As part of the project, the study
presented in this thesis establishes that FGF21 contributes to the muscle pathology. The results
from the metabolomic analysis and the measured enzyme expression levels show, that essential
features of the metabolic changes of the diseased muscle are mediated by FGF21. It increases the
flux of carbon units into one carbon metabolism via several routes – both serine de novo synthesis
and individual alternative carbon donors – and it increases enzyme expression of the transsulfuration
pathway. However, the results do not exlude the possibility that these changes could be protective
for the organism.
Additionally, shifts in the levels of metabolites in energy metabolism in KO mice with WT back-
ground indicate, that as a hormone FGF21 has in normal physiology an influence on energy
metabolism beyond the regulation of lipolysis in adipose tissue. Further metabolomic inquiries
and replication of the findings of this study will give more detailed knowledge about the actions of
FGF21 in the future.
50
References
Ahola-Erkkila¨, S., Carroll, C., Peltola-Mjo¨sund, K., Tulkki, V., Mattila, I., Seppa¨nen-Laakso, T.,
Oresic, M., Tyynismaa, H. & Suomalainen, A. (2010), ‘Ketogenic diet slows down mitochondrial
myopathy progression in mice’, Hum Mol Genet 19, 1974–1984. DOI: 10.1093/hmg/ddq076.
Ahola, S., Auranen, M., Isohanni, P., Niemisalo, S., Urho, N., Buzkova, J., Velagapudi, V., Lund-
bom, N., Hakkarainen, A., Muurinen, T., Piirila¨, P., Pietila¨inen, K. H. & Suomalainen, A. (2016),
‘Modified atkins diet induces subacute selective ragged-red-fiber lysis in mitochondrial myopathy
patients’, EMBO Mol Med 8, 1234–1248. DOI: 10.15252/emmm.201606592.
Armitage, E., Godzien, J., Alonso-Herranz, V., Lopez-Gonzalvez, A. & Barbas, C. (2015), ‘Miss-
ing value imputation strategies for metabolomics data’, Electrophoresis 36, 3050–3060. DOI:
10.1002/elps.201500352.
Bao, X. R., Ong, S.-E., Goldberger, O., Peng, J., Sharma, R., Thompson, D. A., Vafai, S. B., Cox,
A. G., Marutani, E., Ichinose, F., Goessling, W., Regev, A., Carr, S. A., Clish, C. B. & Mootha,
V. K. (2016), ‘Mitochondrial dysfunction remodels one-carbon metabolism in human cells’, Elife
5:e10575. DOI: 10.7554/eLife.10575.
Bender, R. & Lange, S. (2001), ‘Adjusting for multiple testing - when and how?’, J Clin Epidemiol
54, 343–349.
Breiman, L. (2001), ‘Random forests’, Mach Learn 45, 5–32.
Chadeau-Hyam, M., Campanella, G., Jombart, T., Bottolo, L., Portengen, L., Vineis, P., Li-
quet, B. & Vermeulen, R. C. (2013), ‘Deciphering the complex: Methodological overview of
statistical models to derive omics-based biomarkers’, Environ Mol Mutagen 54, 542–557. DOI:
10.1002/em.21797.
Chang, W. (2013), R Graphics Cookbook, O’Reilly.
Chen, W. W., Freinkman, E., Wang, T., Birsoy, K. & Sabatini, D. M. (2016), ‘Absolute quantifica-
tion of matrix metabolites reveals the dynamics of mitochondrial metabolism’, Cell 166, 1324–
1337. DOI: 10.1016/j.cell.2016.07.040.
Copeland, W. (2008), ‘Inherited mitochondrial diseases of DNA replication’, Annu Rev Med 59, 131–
146.
Dieterle, F., Ross, A., Schlotterbeck, G. & Senn, H. (2006), ‘Method to account for dilution of
complex biological mixtures. application in 1H NMR metabonomics’, Anal Chem 78, 4281–4290.
DOI 10.1021/ac051632c.
51
Ducker, G. S. & Rabinowitz, J. D. (2017), ‘One-carbon metabolism in health and disease’, Cell
Metab 25, 27–43. DOI: 10.1016/j.cmet.2016.08.009.
Ebbels, T. M. D. & Iorio, M. D. (2011a), Statistical data analysis in metabolomics, in M. P. H.
Stumpf, D. J. Balding & M. Girolami, eds, ‘Handbook of Statistical Systems Biology’, 1 edn,
John Wiley and Sons, Ltd, chapter 8, pp. 163–180. ISBN 978-0-470-71086-9.
Ebbels, T. M. D. & Iorio, M. D. (2011b), Statistical data analysis in metabolomics, in M. P. Stumpf,
D. J. Balding & M. Girolami, eds, ‘Handbook of Statistical Systems Biology’, John Wiley et Sons,
Ltd, chapter 8, pp. 163–180. ISBN 978-0-470-71086-9.
Edgar, A. J. (2002), ‘The human l-threonine 3-dehydrogenase gene is an expressed pseudogene’,
BMC Genet 3. DOI: 10.1186/1471-2156-3-18.
Esteitie, N., Hinttala, R., Wibom, R., Nilsson, H., Hance, N., Naess, K., Tea¨r-Fahnehjelm, K., von
Do¨beln, U., Majamaa, K. & Larsson, N.-G. (2005), ‘Secondary metabolic effects in complex I
deficiency’, Ann Neurol 58, 544–552. DOI: 10.1002/ana.20570.
Fischer, F. M. & Marator-Flier, E. (2016), ‘Understanding the physiology of FGF21’, Annu Rev
Physiol 78, 223–241. DOI: 10.1146/annurev-physiol-021115-105339.
Goffart, S., Cooper, H., Tyynismaa, H., Wanrooij, S., Suomalainen, A. & Spelbrink, J. (2009),
‘Twinkle mutations associated with autosomal dominant progressive external ophthalmoplegia
lead to impaired helicase function and in vivo mtDNA replication stalling’, Hum Mol Genet
18, 328–340. DOI: 10.1093/hmg/ddn359.
Goodpaster, B. H. & Sparks, L. M. (2017), ‘Metabolic flexibility in health and disease’, Cell Metab
25, 1027–1037. DOI: 10.1016/j.cmet.2017.04.015.
Gorman, G. S., Chinnery, P. F., DiMauro, S., Hirano, M., Koga, Y., McFarland, R., Suomalainen,
A., Thorburn, D. R., Zeviani, M. & Turnbull, D. M. (2016), ‘Mitochondrial diseases’, Nat Rev
Disease Primers 2, 1–22. DOI: 10.1038/nrdp.2016.80.
Gowda, H., Ivanisevic, J., Johnson, C., Kurczy, M., Benton, P., Rinehart, D., Nguyen, T., Ray,
J., Kuehl, J., Arevalo, B., Westenskow, P., Wang, J., Arkin, A., Deutschbauer, A., Patti, G. &
Siuzdak, G. (2014), ‘Interactive XCMS online: Simplifying advanced metabolomic data processing
and subsequent statistical analyses’, Anal Chem . DOI: 10.1021/ac500734c.
Haug, K., Salek, R. M., Conesa, P., Hastings, J., de Matos, P., Rijnbeek, M., Mahendraker, T.,
Williams, M., Neumann, S., Rocca-Serra, P., Maguire, E., Gonzalez-Beltra, A., Sansone, S.-A.,
Griffin, J. L. & Steinbeck, C. (2012), ‘Metabolights–an open-access general-purpose repository
52
for metabolomics studies and associated meta-data’, Nucleic Acids Res 41, D781–D786. DOI:
10.1093/nar/gks1004.
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R.,
Mohammadi, M., Esser, V., Elmquist, J., Gerard, R., Burgess, S., Hammer, R., Mangelsdorf, D.
& Kliewer, S. (2007), ‘Endocrine regulation of the fasting response by PPARα-mediated induction
of fibroblast growth factor 21’, Cell Metab 5, 415–425. DOI: 10.1016/j.cmet.2007.05.003.
Johnson, C. H., Ivanisevic, J. & Siuzdak, G. (2016), ‘Metabolomics: beyond biomarkers and towards
mechanisms’, Nat Rev Mol Cell Bio 17, 451–459.
Kalogeropoulou, A. (2011), Pre-processing and analysis of high-dimensional plant metabolomic
data, Master’s thesis, University of East Anglia, Norwich, England.
Khan, N. A., Nikkanen, J., Yatsuga, S., Jackson, C., Wang, L., Pradhan, S., Kivela¨, R., Pes-
sia, A., Velagapudi, V. & Suomalainen, A. (2017), ‘mTORC1 regulates mitochondrial inte-
grated stress response and mitochondrial myopathy progression’, Cell Metab 26, 419–428. DOI:
10.1016/j.cmet.2017.07.007.
Kharitonenkov, A. & DiMarchi, R. (2017), ‘Fibroblast growth factor 21 night watch: advances and
uncertainties in the field’, J Intern Med 281, 233–246. DOI: 10.1111/joim.12580.
Kharitonenkov, A., Shiyanova, T., Koester, A., Ford, A., Micanovic, R., Galbreath, E., Sandusky,
G., Hammond, L., Moyers, J., Owens, R., Gromada, J., Brozinick, J., Hawkins, E., Wroblewski,
V., Li, D.-S., Mehrbod, F., Jaskunas, S. R. & Shanafelt, A. (2005), ‘FGF-21 as a novel metabolic
regulator’, J Clin Invest 115, 1627–1635.
Kharitonenkov, A., Wroblewski, V., Koester, A., Chen, Y.-F., Clutinger, C., Tigno, X., Hansen,
B., Shanafelt, A. & Etgen, G. (2006), ‘The metabolic state of diabetic monkeys is regulated by
fibroblast growth factor-21’, Endocrinology 148, 774–781. DOI: 10.1210/en.2006-1168.
Kilberg, M., Pan, Y.-X., Chen, H. & Leung-Pineda, V. (2005), ‘Nutritional control of gene expres-
sion: how mammalian cells respond to amino acid limitation’, Annu Rev Nutr 25, 59–85. DOI:
10.1146/annurev.nutr.24.012003.132145.
Koskinen, T., Santavuori, P., Sainio, K., Lappi, M., Kallio, A.-K. & Pihko, H. (1994), ‘Infantile
onset spinocerebellar ataxia with sensory neuropathy: a new inherited disease’, J Neurol Sci
121, 50–56. DOI: 10.1016/0022-510X(94)90156-2.
Koves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., Bain, J., Stevens,
R., Dyck, J. R., Newgard, C. B., Lopashuk, G. D. & Muoio, D. M. (2008), ‘Mitochondrial overload
53
and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance’, Cell Metab
7, 45–57. DOI: 10.1016/j.cmet.2007.10.013.
Lallemand, Y., Luria, V., Haffner-Krausz, R. & Lonai, P. (1998), ‘Maternally expressed PKG-
Cre transgene as a tool for early und uniform activation of the Cre site-specific recombinase’,
Transgenic Res pp. 105–112.
Lehtonen, J. M., Forsstro¨m, S., Bottani, E., Viscomi, C., Baris, O. R., Isoniemi, H., Ho¨ckerstedt, K.,
O¨sterlund, P., Hurme, M., Jylha¨va¨, J., Leppa¨, S., Markkula, R., Helio¨, T., Mombelli, G., Uusi-
maa, J., Laaksonen, R., Laaksovirta, H., Auranen, M., Zeviani, M., Smeitnik, J., Wiesner, R. J.,
Nakada, K., Isohanni, P. & Suomalainen, A. (2016), ‘FGF21 is a biomarker for mitochondrial
translation and mtDNA maintenance disorders’, Neurology 87, 2290–2299.
Liu, X. & Locasale, J. W. (2017), ‘Metabolomics: A Primer’, Trends Biochem Sci 1, 1. DOI:
10.1016/j.tibs.2017.01.004.
Maruyama, R., Shimizu, M., Li, J., Inoue, J. & Sato, R. (2016), ‘Fibroblast growth factor 21 induc-
tion by activating transcription factor 4 is regulated through three amino acid response elements
in its promoter region’, Biosci Biotech Bioch 5, 929–934. DOI: 10.1080/09168451.2015.1135045.
Mary-Huard, T. & Robin, S. (2011), Introduction to statistical methods for complex systems, in
M. P. Stumpf, D. J. Balding & M. Girolami, eds, ‘Handbook of Statistical Systems Biology’,
John Wiley et Sons, Ltd, chapter 2, pp. 15–38. ISBN 978-0-470-71086-9.
Miller, L. (2010), ‘Analyzing gels and western blots with ImageJ’. read on 27.11.2016.
URL: http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-image-j/
Minard, A. Y., Tan, S.-X., Yang, P., Fazakerley, D. J., Domanova, W., Parker, B. L., Humphrey,
S. J., Jothi, R., Sto¨ckli, J. & James, D. E. (2016), ‘mTORC1 is a major regulatory node in the
FGF21 signaling network in adipocytes’, Cell Rep 17, 29–37. DOI: 10.1016/j.celrep.2016.08.086.
Muoio, D. M. (2014), ‘Metabolic inflexibility: When mitochondrial indecision leads to metabolic
gridlock’, Cell 159, 1253–1353. DOI: 10.1016/j.cell.2014.11.034.
Muoio, D. M., Noland, R. C., Kovalik, J.-P., Seiler, S. E., Davies, M. N., DeBalsi, K. L., Ilkayeva,
O. R., Stevens, R. D., Kheterpal, I., Zhang, J., Covington, J. D., Bajpeyi, S., Ravussin, E.,
Kraus, W., Koves, T. R. & Mynatt, R. L. (2012), ‘Muscle-specific deletion of carnitine acetyl-
transferase compromises glucose tolerance and metabolic flexibility’, Cell Metab 15, 764–778.
DOI: 10.1016/j.cmet.2012.04.005.
Nikkanen, J., Forsstro¨m, S., Euro, L., Paetau, I., Kohnz, R. A., Wang, L., Chilov, D., Viinama¨ki, J.,
Roivainen, A., Marjama¨ki, P., Liljenba¨ck, H., Ahola, S., Buzkova, J., Terzioglu, M., Khan, N. A.,
54
Pirnes-Karhu, S., Paetau, A., Lo¨nnqvist, T., Sajantila, A., Isohanni, P., Tyynismaa, H., Nomura,
D. K., Battersby, B. J., Velagapudi, V., Carroll, C. J. & Suomalainen, A. (2016), ‘Mitochondrial
DNA replication defects disturb cellular dNTP pools and remodel one-carbon metabolism’, Cell
Metab 23, 635–648. DOI 10.1016/j.cmet.2016.01.019.
Nilsson, R., Jain, M., Madhusudhan, N., Sheppard, N. G., Strittmatter, L., Kampf, C., Huang,
J., Asplund, A. & Mootha, V. K. (2014), ‘Metabolic enzyme expression highlights a key
role for MTHFD2 and the mitochondrial folate pathway in cancer’, Nat Commun 5. DOI:
10.1038/ncomms4128.
Nishimura, T., Nakatake, Y., Konishi, M. & Itoh, N. (2000), ‘Identification of a novel FGF, FGF-21,
preferentially expressed in the liver’, Biochim Biophys Acta 1492, 203–206.
Noland, R. C., Koves, T. R., Seiler, S. E., Lum, H., Lust, R. M., Ilkayeva, O., Stevens, R. D.,
Hegardt, F. G. & Muoio, D. M. (2009), ‘Carnitine insufficiency caused by aging and overnutrition
compromises mitochondrial performance and metabolic control’, J Biol Chem 284, 22840–22852.
DOI: 10.1074/jbc.M109.032888.
Nunnari, J. & Suomalainen, A. (2012), ‘Mitochondria: In sickness and in health’, Cell 148, 1145–
1159. DOI: 10.1016/j.cell.2012.02.035.
Ostojic, S. M. (2015), ‘Cellular bioenergetics of guanidinoacetic acid: the role of mitochondria’, J
Bioenerg Biomembr 47, 369–372. DOI: 10.1007/s10863-015-9619-7.
Pereira, R. O., Tadinada, S. M., Zasadny, F. M., Oliveira, K. J., Pires, K. M. P., Olvera, A., Jeffers,
J., Souvenir, R., Mcglaufin, R., Seei, A., Funari, T., Sesaki, H., Potthoff, M. J. & Adams, C. M.
(2017), ‘OPA1 deficiency promotes secretion of FGF21 from muscle that prevents obesity and
insulin resistance’, EMBO J 36, 2126–2145. DOI: 10.15252/embj.201696179.
Pfeffer, G., Horvath, R., Klopstock, T., Mootha, V. K., Suomalainen, A., Koene, S., Hirano, M.,
Zeviani, M., Bindoff, L. A., Yu-Wai-Man, P., Hanna, M., Carelli, V., McFarland, R., Majamaa,
K., Turnbull, D. M., Smeitink, J. & Chinnery, P. F. (2013), ‘New treatments for mitochon-
drial disease–no time to drop our standards’, Nat Rev Neurol 9, 474–481. DOI: 10.1038/nrneu-
rol.2013.129.
Potthoff, M. (2016), ‘A new frontier in FGF21 biology’, Nat Rev Endocrinol . DOI:
10.1038/nrendo.2016.206.
Potthoff, M., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B.,
Mangelsdorf, D., Kliewer, S. & Burgess, S. (2009), ‘FGF21 induces PGC-1α and regulates carbo-
hydrate and fatty acid metabolism during the adaptive starvation response’, PNAS 106, 10853–
10858. DOI: 10.1073 pnas.0904187106.
55
Ressom, H. W., Varghese, R. S., Zhang, Z., Xuan, J. & Clarke, R. (2008), ‘Classification algo-
rithms for phenotype prediction in genomics and proteomics’, Front Biosci 13, 691–708. DOI:
10.2741/2712.
Salminen, A., Kaarniranta, K. & Kauppinen, A. (2017), ‘Integrated stress response stimu-
lates FGF21 expression: Systemic enhancer of longevity’, Cell Signal 40, 10–21. DOI:
10.1016/j.cellsig.2017.08.009.
Schmittgen, T. D. & Livak, K. J. (2008), ‘Analyzing real-time PCR data by the comparative Ct
method’, Nat Protoc 3, 1101–1108. DOI: 10.1038/nprot.2008.73.
Seiler, S. E., Martin, O. J., Noland, R. C., Slentz, D. H., DeBalsi, K. L., Ilkayeva, O. R., An, J.,
Newgard, C. B., Koves, T. R. & Muoio, D. M. (2014), ‘Obesity and lipid stress inhibit carnitine
acetyltransferase acivity’, J Lipid Res 55, 635–645. DOI: 10.1194/jlr.M043448.
Shoffner, J. M., Lott, M. T., Voljavec, A. S., Soueidan, S. A., Costigan, D. A. & Wallace, D. C.
(1989), ‘Spontaneous Kearns-Sayre/chronic external opththalmoplegia plus syndrome associated
with a mitochondrial DNA deletion: A slip-replication model and metabolic therapy’, Proc Natl
Acad Sci USA 86, 7952–7956.
Smeitnik, J. A., Zeviani, M., Turnbull, D. M. & Jacobs, H. T. (2006), ‘Mitochondrial medicine:
A metabolic prespective on the pathology of oxidative phosphorylation disorders’, Cell Metab
3, 9–13. DOI: 10.1016/j.cmet.2005.12.001.
Sonoda, J., Chen, M. Z. & Baruch, A. (2017), ‘FGF21-receptor agonists: an emerging therapeutic
class for obesity-related diseases’, Horm Mol Biol Clin Investig 30. DOI: 10.1515/hmbci-2017-
0002.
Spelbrink, J. N., Li, F.-Y., Tiranti, V., Nikali, K., Yuan, Q.-P., Tariq, M., Wanrooij, S., Garrido, N.,
Comi, G., Morandi, L., Santoro, L., Toscano, A., Fabrizi, G.-M., Somer, H., Croxen, R., Beeson,
D., Poulton, J., Suomalainen, A., Jacobs, H. T., Zeviani, M. & Larsson, C. (2001), ‘Human
mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage
T7 gene 4-like protein localised in mitochondria’, Nat Genet 28, 223–231. DOI: 10.1038/90058.
Srivastava, S. & Moraes, C. (2005), ‘Double-strand breaks of mouse muscle mtdna promote large
deletions similar to multiple mtDNA deletions in humans’, Hum Mol Genet 14, 893–902. DOI:
10.1093/hmg/ddi082.
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjeed, S., Eberta, B. L., Gillette, M. A.,
Paulovichg, A., Pomeroyh, S. L., Goluba, T. R., Landera, E. S. & Mesirov, J. P. (2005), ‘Gene
56
set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression
profiles’, PNAS 102, 15545–15550. DOI: 10.1073 pnas.0506580102.
Suomalainen, A. (2011b), ‘Therapy for mitochondrial disorders: Little proof, high research activity,
some promise’, Semin Fetal Neonat M 16, 236–240. DOI: 10.1016/j.siny.2011.05.003.
Suomalainen, A., Elo, J. M., Pietila¨inen, K. H., Hakonen, A. H., Sevastianova, K., Korpela, M.,
Isohanni, P., Marjavaara, S. K., Tyni, T., Kiuru-Enari, S., Pihko, H., Darin, N., Ounap, K.,
Kluijtmans, L. A. J., Paetau, A., Buzkova, J., Bindoff, L. A., Annunen-Rasila, J., Uusimaa, J.,
Rissanen, A., Yki-Ja¨rvinen, H., Hirano, M., Tulinius, M., Smeitnik, J. & Tyynismaa, H. (2011a),
‘FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a
diagnostic study’, Lancet 10, 806–818. DOI 10.1016/S1474- 4422(11)70155-7.
Suomalainen, A., Majander, A., Haltia, M., Somer, H., Lo¨nnqvist, J., Savontaus, M.-L. & Peltonen,
L. (1992), ‘Multiple deletions of mitochondrial DNA in several tissues of a patient with severe
retarded depression and familial progressive external ophthalmoplegia’, J Clin Invest 90, 61–66.
DOI: 10.1172/JCI115856.
Tautenhahn, R., Patti, G., Rinehart, D. & Siuzdak, G. (2012), ‘XCMS online: A web-based platform
to process untargeted metabolomic data’, Anal Chem 84, 5035–5039. DOI: 10.1021/ac300698c.
Thorburn, D. R. (2004), ‘Mitochondrial disorders: Prevalence, myths and advances’, J Inherit
Metab Dis 27, 349–362. DOI: 10.1023/B:BOLI.0000031098.41409.55.
Tusher, V. G., Tibshirani, R. & Chu, G. (2001), ‘Significance analysis of microarrays applied to the
ionizing radiation response’, PNAS 98, 5116–5121. DOI 10.1073 pnas.091062498.
Tyynismaa, H., Carroll, C. J., Raimundo, N., Ahola-Erkkila¨, S., Wenz, T., Ruhanen, H., Guse,
K., Hemminki, A., Peltola-Mjosund, K. E., Tulkki, V., Oresic, M., Moraes, C. T., Pietila¨inen,
K., Hovatta, I. & Suomalainen, A. (2010), ‘Mitochondrial myopathy induces a starvation-like
response’, Hum Mol Genet 19, 3948–3958. DOI 10.1093/hmg/ddq310.
Tyynismaa, H., Mjosund, K. P., Wanrooij, S., Lappalainen, I., Ylikallio, E., Jalanko, A., Spelbrink,
J. N., Paetau, A. & Suomalainen, A. (2005), ‘Mutant mitochondrial helicase Twinkle causes
multiple mtDNA deletions and a late-onset mitochondrial disease in mice’, P Natl Acad Sci USA
102, 17687–17692. DOI 10.1073 pnas.0505551102.
Tyynismaa, H. & Suomalainen, A. (2009), ‘Mouse models of mitochondrial DNA defects and their
relevance for human disease’, EMBO Rep 10, 137–144. DOI: 10.1038/embor.2008.242.
Wold, S., Sjo¨stro¨m, M. & Eriksson, L. (2001), ‘PLS-regression: a basic tool of chemometrics’,
Chemometr Intell Lab 58, 109–130.
57
Worley, B. & Powers, R. (2013), ‘Multivariate analysis in metabolomics’, Current Metabolomics
1, 92–107.
Xi, B., Gu, H., Baniasadi, H. & Raftery, D. (2014), ‘Statistical analysis and modeling of mass
spectrometry-based metabolomics data’, Methods Mol Biol 1198, 333–353. DOI: 10.1007/978-1-
4939-1258-2-22.
Xia, J., Psychogios, N., Young, N. & Wishart, D. S. (2009), ‘MetaboAnalyst: a web server
for metabolomic data analysis and interpretation’, Nucleic Acids Res 37, W652–W660. DOI
10.1093/nar/gkp356.
Xia, J. & Wishart, D. S. (2010), ‘MSEA: a web-based tool to identify biologically meaning-
ful patterns in quantitative metabolomic data’, Nucleic Acids Res 38, W71–W77. DOI:
10.1093/nar/gkq329.
Xia, J. & Wishart, D. S. (2016), ‘Using MetaboAnalyst 3.0 for comprehensive metabolomics data
analysis’, Curr Protoc Bioinform 55, 14.10.1–14.10.91. DOI 10.1002/cpbi.11.
Ylikallio, E. & Suomalainen, A. (2012), ‘Mechanisms of mitochondrial diseases’, Ann Med 44, 41–59.
DOI 10.3109/07853890.2011.598547.
Zhang, Z., Tan, M., Xie, Z., Dai, L., Chen, Y. & Zhao, Y. (2010), ‘Identification of lysine succiny-
lation as a new post-translational modification’, Nat Chem Biol 7, 58–66. DOI: 10.1038/nchem-
bio.495.
Zong, W.-X., Rabinowitz, J. D. & White, E. (2016), ‘Mitochondria and cancer’, Mol Cell 61, 667–
676. DOI: 10.1016/j.molcel.2016.02.011.
58
A Appendix
N:o Metabolite KEGG HMDB
1 1-Methylhistamine C05127 HMDB00898
2 2-Aminoisobutyrate C03665 HMDB01906
3 3-Hydroxanthranilate C00632 HMDB01476
4 4-Pyridoxate C00847 HMDB00017
5 5-Methyl-THF C00440 HMDB01396
6 5-10-Methenyl-THF C00445 HMDB01354
7 Acetoacetate C00164 HMDB00060
8 Acetylcarnitine C02571 HMDB00201
9 Adenine C00147 HMDB00034
10 Adenosine C00212 HMDB00050
11 Alanine C00041 HMDB00161
12 Allantoin C01551 HMDB00462
13 AMP C00020 HMDB00045
14 Arachidyl carnitine NA HMDB06460
15 Arginine C00062 HMDB00517
16 Asparagine C00152 HMDB00168
17 Aspartate C00049 HMDB00191
18 Betaine C00719 HMDB00043
19 Carnitine C00318 HMDB00062
20 Chenodeoxycholate C02528 HMDB00518
21 Choline C00114 HMDB00097
22 Citrulline C00327 HMDB00904
23 Creatine C00300 HMDB00064
24 Creatinine C00791 HMDB00562
25 Cysteine C00097 HMDB00574
26 Cytidine C00475 HMDB00089
27 Cytosine C00380 HMDB00630
28 D-Ribose-5-P C00117 HMDB01548
29 Decanoylcarnitine NA HMDB00651
30 Deoxycytidine C00881 HMDB00014
31 Deoxyuridine C00526 HMDB00012
32 Dimethylglycine C01026 HMDB00092
33 Dodecanoylcarnitine NA HMDB02250
34 Folate C00504 HMDB00121
35 G-Glutamylcysteine C00669 HMDB01049
36 Glutamate C00025 HMDB00148
37 Glutamine C00064 HMDB00641
38 Glutathione C00127 HMDB00125
39 Glyceraldehyde C02154 HMDB01051
40 Glycine C00037 HMDB00123
i
41 Glycocholate C01921 HMDB00138
42 Guanidoacetate C00581 HMDB00128
43 Guanosine C00387 HMDB00133
44 Hexanoylcarnitine NA HMDB00705
45 Hippurate C01586 HMDB00714
46 Histidine C00135 HMDB00177
47 Hypoxanthine C00262 HMDB00157
48 IMP C00130 HMDB00175
49 Inosine C00294 HMDB00195
50 Isobutyryl-L-carnitine NA HMDB00736
51 Isoleucine C00407 HMDB00172
52 Isovalerylcarnitine NA HMDB00688
53 Kynurenine C01718 HMDB00684
54 Leucine C00123 HMDB00687
55 Lysine C00047 HMDB00182
56 Methionine C00073 HMDB00696
57 MTA NA HMDB01173
58 Myoinositol C00137 HMDB00211
59 N5-Formyl-THF C03479 HMDB01562
60 NAD C00003 HMDB00902
61 Neopterin C05926 HMDB00845
62 Niacinamide C00153 HMDB01406
63 Normetanephrine C05589 HMDB00819
64 Octanoylcarnitine C02838 HMDB00791
65 Ornithine C00077 HMDB00214
66 Orotate C00295 HMDB00226
67 Palmitoylcarnitine C02990 HMDB00222
68 Pantothenate C00864 HMDB00210
69 Phenylalanine C00079 HMDB00159
70 Phosphoethanolamine C00346 HMDB00224
71 Proline C00148 HMDB00162
72 Propionylcarnitine C03017 HMDB00824
73 SAH C00021 HMDB00939
74 Serine C00065 HMDB00187
75 Sorbitol C00794 HMDB00247
76 Spermidine C00315 HMDB01257
77 Stearoylcarnitine NA HMDB00848
78 Succinate C00042 HMDB00254
79 Sucrose C00089 HMDB00258
80 Taurine C00245 HMDB00251
ii
81 Taurochenodesoxycholate C05465 HMDB00951
82 Taurocholate C05122 HMDB00036
83 Tetradecanoylcarnitine NA HMDB05066
84 THF C00101 HMDB01846
85 Threonine C00188 HMDB00167
86 Trimethylamine N-oxide C01104 HMDB00925
87 Tryptophan C00078 HMDB00929
88 Tyrosine C00082 HMDB00158
89 UDP Glucose C00029 HMDB00286
90 Uracil C00106 HMDB00300
91 Valine C00183 HMDB00883
92 Xanthine C00385 HMDB00292
Table A1: A list of all metabolites measured in this study and their KEGG (Kyoto Encyclopedia
of Genes and Genoms) and HMDB (Human Metabolome Database) compound numbers.
Amino acids and derivatives alanine, arginine, asparagine, aspartic acid, cit-
rulline, cysteine, glutamic acid, glutamine, glycine,
histidine, isoleucine, kynurenine, leucine, lysine, me-
thionine, ornithine, phenylalanine, proline, serine,
threonine, tryptophan, tyrosine, valine
Acyl carnitines acetylcarnitine, arachidyl carnitine, carnitine, de-
canoylcarnitine, dodecanoylcarnitine, hexanoylcarni-
tine, isobutyryl-l-carnitine, isovalerylcarnitine, oc-
tanoylcarnitine, palmitoylcarnitine, propionylcarni-
tine, stearoylcarnitine, tetradecanoylcarnitine
Folate cycle 5-methyl-THF, 5,10-metheny-THF, folic acid, N5-
formyl-THF, THF
Nucleobases and related adenine, adenosine, allantoin, AMP, cytidine, cyto-
sine, deoxycytidine, deoxyuridine, guanosine, hypox-
anthine, IMP, inosine, MTA, NAD, neopterin, SAH,
uracil, xanthine
B-vitamins and degradation products 4-pyridoxate, niacinamide, orotate, pantothenate
Bile acids chenodeoxycholate, choline, glycocholate, taurochen-
odesoxycholate, taurocholate
Sugars and related D-ribose-5-P, glyceraldehyde, myoinositol, sorbitol,
sucrose, UDP glucose
Carboxylic acids and amines 1-methylhistamine, 2-aminoisobutyrate, 3-
hydroxanthranilate, acetoacetate, betaine, crea-
tine, creatinine, dimethylglycine, guanidinoacetate,
hippuric acid, spermidine, succinate
Other G-glutamylcysteine, glutathione, normetanephrine,
phosphoethanolamine, taurine, trimethylamine-N-
oxide
Table A2: All analysed metabolites organised by chemical or biochemical compound classes.
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Figure A1: PLS-DA cross validation and permutations.
iv
Metabolite p.value FDR Fisher’s LSD
Succinate 0.0005 0.027 Del - FGF21 KO; FGF21 KO Del - FGF21 KO; WT
- FGF21 KO
Glutamate 0.0009 0.027 Del - FGF21 KO; Del - FGF21 KO Del; Del - WT
Betaine 0.0014 0.027 Del - FGF21 KO; Del - WT; FGF21 KO Del - FGF21
KO
Phosphoethanolamine 0.0015 0.027 Del - FGF21 KO; Del - FGF21 KO Del; Del - WT
Deoxyuridine 0.0018 0.027 FGF21 KO Del - Del; Del - WT; FGF21 KO - WT;
FGF21 KO Del - WT
Creatine 0.0019 0.027 Del - FGF21 KO; FGF21 KO Del - FGF21 KO; WT
- FGF21 KO
Guanidoacetate 0.0021 0.027 Del - FGF21 KO; FGF21 KO Del - FGF21 KO; WT
- FGF21 KO
Threonine 0.0056 0.060 Del - FGF21 KO; Del - FGF21 KO Del; Del - WT
Palmitoylcarnitine 0.0065 0.060 Del - FGF21 KO; FGF21 KO Del - FGF21 KO;
FGF21 KO Del - WT
Normetanephrine 0.0070 0.060 Del - FGF21 KO; FGF21 KO Del - FGF21 KO
Glutamine 0.0074 0.060 Del - FGF21 KO; FGF21 KO Del - FGF21 KO
Taurine 0.0078 0.060 Del - FGF21 KO; FGF21 KO Del - FGF21 KO; WT
- FGF21 KO
Niacinamide 0.0088 0.062 Del - FGF21 KO; Del - FGF21 KO Del; Del - WT
Taurocholate 0.0096 0.063 Del - FGF21 KO; FGF21 KO Del - FGF21 KO
Table A3: The top 15 metabolites with the lowest p-value in ANOVA.
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Figure A2: Metabolites with the most weight in classification in the PLS-DA and RF models ranked
by (left) variable importance in projection (VIP) scores in PLS-DA and (right) mean decrease
accuracy (MDA) in RF.
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Figure A3: Folate cycle intermediates. Data presented as fold change compared to WT. THF
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p_Del_wt p_Del_DelKO p_Del_KO p_DelKO_wt p_KO_wt p_DelKO_KO
0.1344 0.9453 0.0288 0.3265 0.3757 0.1379
fc_wt fc_KO fc_del fc_delKO
1 0.752 1.468 1.437
Valine
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p_Del_wt p_Del_DelKO p_Del_KO p_DelKO_wt p_KO_wt p_DelKO_KO
0.1566 0.1135 0.0128 0.8802 0.228 0.0465
fc_wt fc_KO fc_del fc_delKO
1 0.865 1.193 1.015
Xanthine
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p_Del_wt p_Del_DelKO p_Del_KO p_DelKO_wt p_KO_wt p_DelKO_KO
0.6078 0.8754 0.1714 0.7877 0.3033 0.3193
fc_wt fc_KO fc_del fc_delKO
1 0.709 1.177 1.109xvii
1−Methylhistamine
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p_Del_wt p_Del_DelKO p_Del_KO p_DelKO_wt p_KO_wt p_DelKO_KO
0.176 0.6348 0.2631 0.1715 0.025 0.6492
fc_wt fc_KO fc_del fc_delKO
1 4.253 2.509 3.375
2−Aminoisobutyrate
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p_Del_wt p_Del_DelKO p_Del_KO p_DelKO_wt p_KO_wt p_DelKO_KO
0.1701 0.395 0.0098 0.4209 0.1511 0.0129
fc_wt fc_KO fc_del fc_delKO
1 0.827 1.187 1.091
3−Hydroxanthranilate
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p_Del_wt p_Del_DelKO p_Del_KO p_DelKO_wt p_KO_wt p_DelKO_KO
0.571 0.3484 0.0876 0.7843 0.0819 0.0387
fc_wt fc_KO fc_del fc_delKO
1 0.772 0.933 1.038
4−Pyridoxate
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WT
FG
F2
1 K
O
De
let
or
De
l F
GF
21
 KO
l
l
l
ll
l
l
l
l
l
l
ll
ll
ll l
l
l
l
l
l
p_Del_wt p_Del_DelKO p_Del_KO p_DelKO_wt p_KO_wt p_DelKO_KO
0.1934 0.304 0.2915 0.8397 0.6706 0.8497
fc_wt fc_KO fc_del fc_delKO
1 0.899 0.713 0.945
5−Methyl−THF
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p_Del_wt p_Del_DelKO p_Del_KO p_DelKO_wt p_KO_wt p_DelKO_KO
0.0194 0.2737 0.5387 0.2779 0.4611 0.9765
fc_wt fc_KO fc_del fc_delKO
1 1.235 1.419 1.226
5,10−Metheny−THF
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p_Del_wt p_Del_DelKO p_Del_KO p_DelKO_wt p_KO_wt p_DelKO_KO
0.852 0.1008 0.6585 0.0711 0.4923 0.1419
fc_wt fc_KO fc_del fc_delKO
1 1.123 1.039 1.495
5,10−Methylene−THF
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p_Del_wt p_Del_DelKO p_Del_KO p_DelKO_wt p_KO_wt p_DelKO_KO
fc_wt fc_KO fc_del fc_delKO
1 6.415 3.161 4.769 xviii
